WO2000056338A1 - Quinazoline formulations and therapeutic use thereof - Google Patents

Quinazoline formulations and therapeutic use thereof Download PDF

Info

Publication number
WO2000056338A1
WO2000056338A1 PCT/US2000/007066 US0007066W WO0056338A1 WO 2000056338 A1 WO2000056338 A1 WO 2000056338A1 US 0007066 W US0007066 W US 0007066W WO 0056338 A1 WO0056338 A1 WO 0056338A1
Authority
WO
WIPO (PCT)
Prior art keywords
amino
dimethoxyquinazoline
pharmaceutical composition
och
whi
Prior art date
Application number
PCT/US2000/007066
Other languages
French (fr)
Inventor
Seang Yiv
Mingshu Li
Fatih M. Uckun
Original Assignee
Parker Hughes Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Parker Hughes Institute filed Critical Parker Hughes Institute
Priority to EP00914991A priority Critical patent/EP1162974A1/en
Priority to JP2000606242A priority patent/JP2002539262A/en
Priority to AU36301/00A priority patent/AU3630100A/en
Priority to CA002366998A priority patent/CA2366998A1/en
Publication of WO2000056338A1 publication Critical patent/WO2000056338A1/en
Priority to US09/960,464 priority patent/US20020111360A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes

Definitions

  • This application relates to new formulations for poorly water soluble quinazoline compounds and therapeutic methods for the treatment of cancers and treatment of allergic disorders by administering quinazoline formulations.
  • Quinazoline compounds have been suggested as useful compounds in the treatment of cell growth and differentiation characterized by activity of the human epidermal growth factor receptor type2 (HER2). See, for example, Myers etal., U.S. Patent No. 5,721,237. Some quinazoline derivatives have been suggested as useful as anti-cancer agents for the treatment of specific receptor tyrosine kinase-expressing cancers, especially those expressing epithelial growth factor (EGF) receptor tyrosine kinase. See, for example, Barker et. al., U.S. Patent No. 5,457,105. It is generally taught that quinazolines exert their anti-tumor effects via tyrosine kinase inhibition.
  • EGF epithelial growth factor
  • a series of water soluble quinazoline formulations were prepared and analyzed for therapeutic activities, including anti-cancer activities, particularly against JAK3 receptor.
  • the invention provides novel water soluble quinazoline formulations, as disclosed below, as well as therapeutic methods utilizing these formulations.
  • One aspect of the invention is a pharmaceutical composition
  • a pharmaceutical composition comprising a dialkoxyquinazoline compound, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable non-topic lipid based carrier, diluent or vehicle.
  • Another aspect of the invention is a method of administering a dialkoxyquinazoline compound to a mammal, the method includes combining the dialkoxyquinazoline compound with a pharmaceutically acceptable lipid-based vehicle to form a pharmaceutical composition and administering the pharmaceutical composition to the mammal.
  • Another aspect of the invention is a method of administering a dimethoxyquinazoline compound to a mammal.
  • the method includes providing a pharmaceutical composition including dimethoxyquinazoline compound in the salt form, PEG phospholipids, a cosolvent system, and administering the pharmaceutical composition to the mammal.
  • Figure 1 is a graph showing the solubility of WHI-P131 chloride as a function of PEG 300 and PEG 200 concentration.
  • Figure 2 is a graph showing solubility of WHI-P131 chloride as a function of PEG2000-DPPE concentration.
  • Figure 3 is a ternary phase diagram showing the location of a single phase microemulsion region.
  • Figure 4 is a flow diagram of the cumulative solubilization enhancement of W ⁇ I-P131 with the formulations of the invention.
  • Figure 5 is a graph showing the plasma concentration-time curves following i.v. bolus injection of WHI-P131 formulations of the invention in mice.
  • Figure 6 is a graph showing mast cell inhibitory "anti-allergic" activity of the formulations of the invention in vitro.
  • Halo is fluoro, chloro, bromo, or iodo.
  • Alkyl, alkanoyl, etc. denote both straight and branched groups; but reference to an individual radical such as "propyl” embraces only the straight chain radical, a branched chain isomer such as “isopropyl” being specifically referred to.
  • (C ⁇ -C 4 )alkyl includes methyl, ethyl, propyl, isopropyl, butyl, iso-butyl, and sec-butyl;
  • (Q-C )alkoxy includes methoxy, ethoxy, propoxy, isopropoxy, butoxy, iso-butoxy, and sec-butoxy;
  • (Q- C 4 )alkanoyl includes acetyl, propanoyl and butanoyl.
  • pharmaceutically acceptable carrier means any material which, when combined with the compound of the invention, allows the compound to retain biological activity, such as the ability to potentiate antibacterial activity of mast cells and macrophages.
  • conjugate means a compound formed as a composite between two or more molecules. More specifically, in the present invention, the quinazoline derivative is bonded, for example, covalently bonded, to cell-specific targeting moieties forming a conjugate compound for efficient and specific delivery of the agent to a cell of interest.
  • targeting moiety means a molecule which serves to deliver the compound of the invention to a specific site for the desired activity. Targeting moieties include, for example, molecules that specifically bind molecules on a specific cell surface.
  • targeting moieties useful in the invention include anti-cell surface antigen antibodies.
  • Cytokines including interleukins and factors such as granulocyte/macrophage stimulating factor (GMCSF) are also specific targeting moieties, known to bind to specific cells expressing high levels of their receptors.
  • GMCSF granulocyte/macrophage stimulating factor
  • prodrug moiety is a substitution group which facilitates use of a compound of the invention, for example by facilitating entry of the drug into cells or administration of the compound.
  • the prodrug moiety may be cleaved from the compound, for example by cleavage enzymes in vivo.
  • prodrug moieties include phosphate groups, peptide linkers, and sugars, which moieties can be hydrolyzed in vivo.
  • inhibitor means to reduce by a measurable amount, or to prevent entirely.
  • to treat means to inhibit or block at least one symptom that characterizes a pathologic condition, in a mammal threatened by, or afflicted with, the condition.
  • the invention is directed towards formulations for delivery of an effective amount of quinazoline to a treatment site.
  • the formulations relate to pharmaceutical compositions that include a quinazoline compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable, lipid— based vehicle or delivery system.
  • the vehicle or delivery system of the quinazoline composition is a nontoxic delivery system or vehicle for parenteral administration.
  • the formulations disclosed enhance the water solubility of quinazoline compounds without loss of biologic activity of the quinazoline compound at the treatment site.
  • Quinazoline compounds include quinazolines having the formula:
  • R a is hydrogen; halo; hydroxy; mercapto; ( -C )hydroxyalkyl, methylenedioxy, ethylenedioxy, benzyloxy,OCF 3> SCF 3 ⁇ SO 3 H, SO 2 F, SO 2 NR 2 R 3 in which R 2 is hydrogen or (C[-C )alkyl and R 3 is hydrogen, (C]-C 4 )alkyl, or phenyl, NR 2 R 4 in which R 2 is as defined above and R 4 is phenyl, or R a a group of the formula
  • R 5 and R are each, independently, hydrogen, ( -C 4 )alkyl, or (C ⁇ -C 4 )perfluoroalkyl
  • R 7 is hydrogen, halo, hydroxy, ( -C 4 )alkyl, (C ⁇ - C )alkoxy, (C ⁇ -C )hydroxyalkyl, or N(R ) 2 in which R is as defined above; n is an integer of 1-4;
  • R b is each, independently, hydrogen; halo; hydroxy; mercapto; ( - C 4 )alkyl, (C[-C 4 )alkoxy, (C ⁇ -C 4 )thioalkyl, (C ⁇ -C )hydroxyalkyl, nitro, cyano, methylenedioxy, ethylenedioxy, COCH 3 , CF 3 ;, OCF 3 ; SCF 3 ; COOH; SO 3 H; SO 2 F; phenyl or phenyl substituted by a group selected from halo, hydroxy, mercapto, (Q- C 4 )alkyl, (C ⁇ -C 4 )alkoxy, (C ⁇ -C 4 )thioalkyl, (Cj-C 4 )hydroxyalkyl, amino, nitro, cyano, CF 3 , COOH, SO 3 H, SO 2 NR 2 R 3 in which R 2 and R 3 are as defined below, and SO 2 F;
  • R a is also benzyloxy substituted on the phenyl portion by a group defined above, NR 2 R 3 in which R 2 is H or (C ⁇ -C 4 )alkyl and R 3 is H, (C ⁇ -C 4 )alkyl, phenyl or phenyl substituted by a group as defined above;
  • R 1 is (C]-C 4 )alkyl, preferably methyl, or a pharmaceutically acceptable salt thereof, such as an acid addition salt.
  • Preferred quinazoline compounds useful in the treatment of tumors are described more fully below and particularly in the Examples.
  • the quinazoline compounds of the invention are useful as pharmaceutical compositions prepared with a therapeutically effective amount of a quinazoline compound and a pharmaceutically acceptable carrier.
  • the quinazoline formulations of the invention can be administered to a mammalian host, such as a human patient in a variety of forms adapted to the chosen route of administration, i.e., orally or parenterally, by intravenous, intramuscular, transdermal or subcutaneous routes.
  • the present invention is especially suitable for parenteral administration, particularly intravenous administration.
  • the amount of quinazoline compounds in such therapeutically useful formulations is such that an effective dosage level will be obtained.
  • the quinazoline formulations may be administered intravenously or intraperitoneally by infusion or injection.
  • Solutions of the quinazoline compounds can be prepared in water, optionally mixed with a nontoxic surfactant.
  • Dispersions can also be prepared in glycerol, liquid polyethylene glycols, triacetin, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
  • the pharmaceutical dosage forms suitable for injection or infusion can include sterile aqueous solutions or dispersions or sterile powders including the quinazoline compounds which are adapted for extemporaneous preparation of sterile injectable or infusible solutions or dispersions, or encapsulated in liposomes.
  • the vehicle is a micellar solution, microemulsion or mixtures thereof.
  • the ultimate dosage form must be sterile, fluid and stable under the conditions of manufacture and storage.
  • the liquid carrier or vehicle can be a solvent or liquid dispersion medium comprising, for example, water, ethanol, a polyol (for example, glycerol, propylene glycol, liquid polyethylene glycols, and the like), vegetable oils, nontoxic glyceryl esters, and suitable mixtures thereof.
  • a polyol for example, glycerol, propylene glycol, liquid polyethylene glycols, and the like
  • vegetable oils nontoxic glyceryl esters, and suitable mixtures thereof.
  • suitable mixtures thereof can be maintained, for example, by the formation of liposomes, by the maintenance of the required particle size in the case of dispersions, such as microemulsions, or by the use of surfactants, such as micellar solutions.
  • Micelles are composed of aggregates consisting of generally 50 or more surfactant molecules. Micelles form in aqueous solutions at surfactant concentrations above the critical micellar concentration (CMC). Micelles have the ability to solubilize lipophilic or amphiphilic compounds. Thus, micellar systems can be used to enhance the solubility of poorly water soluble substances, such as some quinazoline compounds.
  • CMC critical micellar concentration
  • micellar solutions are good solubilizing vehicles for poorly water soluble quinazoline compounds.
  • Micellar system formulations include a quinazoline compound, one or more surfactants, and a carrier.
  • PEGylated phosphatidylethanolamines (1,2- Dipalmitoyl-sn-Glycero-3-Phosphoethanolamine-N-[Poly(ethylene glycol) 5000] and 1 ,2-Dipalmitoyl-sn-Glycero-3-Phosphoethanolamine-N-[Poly(ethylene glycol) 2000]) are effective in enhancing the solubilization of quinazoline compounds.
  • the solubilization enhancement as represented by the amount of solubilized quinazoline compound (in milligram) per gram of surfactant varies with the type of surfactant used and depends on the hydrophobic chain length and polyoxyethylene number of the PEGylated phospholipid.
  • Preferred PEGylated phospholipids include PEG2000-DPPE® and PEG5000-DPPE® and are commercially available from Avanti Polar-Lipids Inc., (Alabaster, AL.).
  • the micellar solution may include a second surfactant such as, block copolymers of ethylene oxide and propylene oxide alone or in addition to the PEGylated phosphatidylethanolamine surfactant.
  • a second surfactant such as, block copolymers of ethylene oxide and propylene oxide alone or in addition to the PEGylated phosphatidylethanolamine surfactant.
  • Preferred block copolymers of ethylene oxide and propylene oxide include; Pluronic F-77, Pluronic F-87, and Pluronic F-88 and are commercially available form BASF Corp., (Mount Olive, NJ.)
  • micellar solution may include a carrier.
  • a preferred carrier is propylene glycol such as 1,2-propanediol.
  • Microemulsions are thermodynamically stable, transparent, dispersions of water and oil, stabilized by an interfacial film of surfactant molecules. Microemulsions are characterized by their submicron particle size of 0.1 ⁇ m or below. Microemulsions and self-emulsifying drug delivery systems (SEDDS) can be used to enhance the solubility of poorly water soluble substances, such as some quinazoline compounds.
  • SEDDS self-emulsifying drug delivery systems
  • Microemulsion system formulations include a quinazoline compound, one or more surfactants, and a carrier.
  • the microemulsion solution may include one or more surfactants. These include block copolymers of ethylene oxide and propylene oxide. Preferred block copolymers of ethylene oxide and propylene oxide include; Pluronic F-77, Pluronic F-87, and Pluronic F-88 and are commercially available from BASF Corp., (Mount Olive, NJ.)
  • surfactants useful in microemulsion solutions include, ethoxylated castor oil such as Cremophor® EL castor oil commercially available from BASF Corp., (Mount Olive, NJ,) and purified soy bean phospholipid or lecithins such as phosphatidylcholine or Phospholipon® 90G commercially available from American Lecithin (Oxford, CT.)
  • ethoxylated castor oil such as Cremophor® EL castor oil commercially available from BASF Corp., (Mount Olive, NJ,) and purified soy bean phospholipid or lecithins such as phosphatidylcholine or Phospholipon® 90G commercially available from American Lecithin (Oxford, CT.)
  • the microemulsion solution may include one or more a carriers.
  • Preferred carriers include, propylene glycol such as 1 ,2-propanediol, and medium chain triglycerides and monoglycerides such as, triglycerides of caprylic/capric acid such as, Captex® 355, Captex® 350 and Captex® 200 commercially available from Abitec Corp., (Columbus, OH.)
  • the prevention of the action of microorganisms in the formulation can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like.
  • isotonic agents for example, sugars, buffers or sodium chloride.
  • Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.
  • Sterile injectable solutions are prepared by incorporating the quinazoline compounds in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filter sterilization.
  • the preferred methods of preparation are vacuum drying and the freeze drying techniques, which yield a powder of the active ingredient plus any additional desired ingredient present in the previously sterile- filtered solutions.
  • the quinazoline formulations of the invention are useful for the treatment of animals, including humans.
  • these quinazoline formulations have been found to be potent inhibitors of tumor cell proliferation and survival, and effective to induce apoptosis of malignant cells.
  • Compounds of the invention have surprisingly been found to be effective for inducing apoptosis and/or cytotoxicity of leukemia cells.
  • 4-(4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline compounds (WHI-P131) of the invention have been found to effectively induce apoptosis in multi-drug resistant leukemia.
  • WHI-P131 is also a potent inhibitor of Janus kinase 3 (JAK 3) and shows considerable clinical potential for treatment of hematologic malignancies as well as allergic disorders.
  • a preferred compound for the treatment of multi-drug resistant leukemia is 4-(3'-bromo-4'-hydroxyphenyl)amino-6,7- dimethoxyquinazoline.
  • Compounds of the invention that are particularly useful for treating leukemia include:
  • Compounds of the invention that are particularly useful for treating breast tumors include:
  • Useful dosages of the quinazoline compounds can be determined by comparing their in vitro activity, and in vivo activity in animal models. Methods for the extrapolation of effective dosages in mice, and other animals, to humans are known to the art; for example, see U.S. Pat. No. 4,938,949.
  • the amount of the quinazoline compounds required for use in treatment will vary not only with the particular salt selected but also with the route of administration, the nature of the condition being treated and the age and condition of the patient and will be ultimately at the discretion of the attendant physician or clinician.
  • a suitable dose will be in the range of from about 0.5 to about 100 mg/kg, e.g., from about 10 to about 75 mg/kg of body weight per day, such as 3 to about 50 mg per kilogram body weight of the recipient per day, preferably in the range of 6 to 90 mg/kg/day, most preferably in the range of 15 to 60 mg/kg/day.
  • the quinazoline compounds are conveniently administered in unit dosage form; for example, containing 5 to 1000 mg, conveniently 10 to 750 mg, most conveniently, 50 to 500 mg of active ingredient per unit dosage form.
  • the quinazoline compounds should be administered to achieve peak plasma concentrations of from about 0.5 to about 75 ⁇ M, preferably, about 1 to 50 ⁇ M, most preferably, about 2 to about 30 ⁇ M. This may be achieved, for example, by the intravenous injection of a 0.05 to 5% solution of the quinazoline compounds. Desirable blood levels may be maintained by continuous infusion to provide about 0.01-5.0 mg/kg/hr or by intermittent infusions containing about 0.4- 15 mg/kg of the quinazoline compounds.
  • the quinazoline compounds may conveniently be presented in a single dose or as divided doses administered at appropriate intervals, for example, as two, three, four or more sub-doses per day.
  • the sub-dose itself may be further divided, e.g., into a number of discrete loosely spaced administrations.
  • the quinazoline compound is targeted to cells where treatment is desired, for example, to leukemia cells, to breast cells, or to other tumor cells.
  • the compound is targeted to the desired cell by conjugation to a targeting moiety that specifically binds the desired cell, thereby directing administration of a conjugated molecule.
  • Useful targeting moieties are ligands which specifically bind cell antigens or cell surface ligands, for example, antibodies against the B cell antigen, CD 19 (such as B43) and the like.
  • targeting moieties are covalently bonded to sites on the quinazoline compound.
  • the targeting moiety which is often a polypeptide molecule, is bound to compounds of the invention at reactive sites, including NH , SH, CHO, COOH, and the like.
  • Specific linking agents are used to join the compounds. Preferred linking agents are chosen according to the reactive site to which the targeting moiety is to be attached.
  • quinazoline compounds may be administered prophylactically, i.e., prior to onset of the pathological condition, or the quinazoline compounds may be administered after onset of the reaction, or at both times.
  • novel hydroxy-substituted quinazoline derivatives of the invention were created by reacting the appropriate substituted anilines with the key starting material, 4-chloro-6,7-dimethoxy quinazoline.
  • Example 3 Chlorine Substituted Quinazoline Compounds Chlorine substituted quinazoline derivatives were synthesized and characterized as discussed above in Example 1. The structures and physical data are shown below:
  • Iodine substituted quinazoline derivatives were synthesized as discussed above in Example 1, and analyzed. The structures and physical data are shown below: Iodine Substituted Quinazoline Compounds
  • IR(KBR) ⁇ max 3391, 3139, 2938, 2850, 1633, 1607, 1567, 1509, 1447, 1359, 1220, 1189, 1055 cm “1 .
  • GC/MS m/z: 314 (M 1, 13.00), 313 (m “ , 72.80), 312(m + -l, 10.20), 296 (5.24), 206(17.50).
  • UV9MeOH 208.0, 215.0, 225.0, 240.0, 330.0 mn.
  • IR(KBr) ⁇ max 3438, 321 1, 3061, 2932, 2834, 1633, 1576, 1509, 1437, 1380, 1276, 1215 cm "1 .
  • GC/MS m z 281(51.00), 253(22.00), 207(88.00).
  • C 2 oH 17 N 3 O 3 .HCl requires: C, 62.66; H, 4.70; N, 10.96%.
  • UV(MeOH) 206.0, 210, 219.0, 225.0, 230.0, 340.0 nm.
  • IR(KBr) ⁇ max 3391, 3165, 3051, 2938, 2840, 1628, 1576, 1504, 1437, 1281, 1215 cm “1 .
  • GC/MS m/z 348(M ⁇ + 1, 7.00), 347(M " , 100.00), 346(M ⁇ 1.22.00), 331(15.00), 330(12.00), 281(23.00), 253(12.00), 207(49.00).
  • IR(KBr) ⁇ max 3407, 3030, 2977, 2840, 1643, 1591 1514, 1463, 1370, 1282, 1230 cm “1 .
  • GC/MS m z 325(M “ +1, 67.00), 324(M “ , 100.00), 323(M ⁇ 1.22.00), 308(17.00), 307(56.00), 306(21.00), 281(2.00), 280(8.00), 264(6.00).
  • WHI-P131 free base was measured in water, propylene glycol, polyethylene glycols (PEGs), ethanol, and triglycerides. The results are summarized in Table 6.
  • the solubility of WHI-P131 is very poor in water. It was about 35 times more soluble in C 8 -C ⁇ 0 medium chain triglyceride (Captex 300) than in water. It was much more soluble in ethanol and hydrophilic cosolvents such as propylene glycol and PEGs.
  • WHI-P131 free base was most soluble in polyethylene glycols of greater than 10%, followed by propylene glycol (1.95%) and ethanol (1.86%). Parallel solubility measurements were also carried out using WHI-
  • PEG300 the solubility continued to increase linearly with increasing PEG concentration, whereas for PEG200, a large increase in slopes occurred near 100%o PEG200. Since the solubility-PEG300 concentration curve is linear over the entire range of water- PEG300 mixtures, WHI-P131 solubilized in these mixtures at concentrations below its saturation point can be used as vehicles for this compound, since their dilution will not result in drug precipitation. In contrast, if one were to dilute by water a 2% WHI-P131 in PEG200, WHI-P131 concentration would fall above the solubility limit and precipitate out. Therefore, PEG300 is more appropriate for use as a cosolvent vehicle in the formulations of WHI-P 131.
  • micellar solutions containing PEGylated phosphatidylethanolamines were exceptionally effective in enhancing the solubilization of WHI-P 131.
  • Table 7 shows the compositions of several mixed micellar solutions containing various amounts of WHI-P131.
  • Micellar solutions using purified soya lecithin (Phospholipon 90G) were feasible when an equal or higher amount of a nonionic surfactant (such as Cremophor EL for example) was also present. With PEGylated phospholipids, the presence of Cremophor EL was not necessary to form micellar solutions.
  • solubility-surfactant concentration curves were plotted.
  • Figure 2 depicts the amount of solubilized WHI-P131 chloride in a solution containing 20% of PEG300, and an increasing amount of PEG2000-DPPE. This figure indicates that, in the absence of surfactant, the solubility of WHI-P131 chloride salt in 20% PEG300 was 2.38 mg/ml. At low surfactant concentrations (below the CMC), the drug solubilization seems to remain unchanged, then increases linearily with surfactant concentration at higher PEG2000-DPPE concentration. The same solubilization characteristics were observed with other micellar solutions.
  • Table 8 the slopes of the linear portions of the plot for a series of nonionic surfactants and cosolvents were used to calculate the solubilization enhancement per unit surfactant or cosolvent concentration.
  • the solubilization enhancement as represented by the amount of solubilized WHI-P131 (in milligram) per gram of surfactant, are shown in Table 8 to vary with the type of surfactants used.
  • the solubilization enhancement depended on the hydrophobic chain length and polyoxyethylene number of the PEGylated phospholipids.
  • PEG2000-DPPE and PEG5000-DPPE seemed to be the most effective solubilizers for WHI-P131 of the three PEGylated phosphatidylethanolamines investigated.
  • Table 8 for comparison purposes are the solubilization enhancements produced by the use of cosolvents. It can be seen that PEGylated surfactants were about 6 to 16 times more effective than cosolvents in producing solubilization enhancement of WHI-P131 chloride salt.
  • a series of ternary phase diagrams were constructed at room temperature, and several microemulsions within the single phase microemulsion region were examined for their capacity to solubilize WHI-P 131.
  • a representative ternary phase diagram depicted in Figure 3 shows the location of the single phase microemulsion region. In this phase diagram, it can be seen that microemulsions containing up to 30% of Captex 300 were possible. These microemulsions were transparent and tolerated dilution very well when mixed with aqueous phases.
  • the drug was first solubilized in the microemulsions chosen from the one phase region of the phase diagram with mild heating, followed by dilution with water or buffer solution at room temperature.
  • the microemulsion composition ME1 depicted in Table 9 was used in pharmacokinetic studies and biological activity assays. This microemulsion was prepared by first solubilizing WHI-P 131 in composition A in the ternary phase diagram, followed by a dilution with water (1 :9). Its volume-weighted average particle diameter as determined by dynamic light scattering was 24.8 nm prior to and 11.4 nm after the incorporation of WHI-P 131 chloride. Thus, the drug incorporation, in this case, resulted in the lowering of the particle size. The solubilization of WHI-P131 was at least 1.8 mg per ml of microemulsion. ME2 was a microemulsion composition obtained from a separate phase diagram not shown.
  • This microemulsion can solubilize at least 2.8 mg of WHI-P131 per ml of microemulsion .
  • ME2 had more than doubled the solubilization of WHI-P 131 in water.
  • These microemulsions can readily be filtered through 0.2 ⁇ m filter, and stored at room temperature. The microemulsions and WHI-P 131 they contained were shown to be stable for an extended time at ambient temperature.
  • WHI-P131 By converting WHI-P131 from its free base to its chloride salt form, a fifty fold increase in solubility was achieved raising the drug concentration from 0.025 mg/ml to 1.2 mg/ml. By adding 20% of PEG300 to the vehicle, the drug concentration further increased to 2.2 mg/ml. Furthermore, an incorporation of 3% of PEG2000-DPPE to the cosolvent vehicle brought the drug solubilization to 4.7mg/ml, which corresponds to a total solubilization enhancement of 190 fold. If a microemulsion formulation instead a cosolvent/micellar solution was used, a total solubilization enhancement of 110 fold. Lead micellar and microemulsion formulations of WHI-P 131 were as active as unformulated WHI-P 131 in DMSO. The miceller formulation inhibited allergic mast cell responses in vitro and prevented anaphy lactic shock in vivo.
  • microemulsions can be used to enhance the solubilization of WHI-P131.
  • the drug incorporation into the microemulsion seemed to be limited to the surfactant interfacial film only which resulted in a relatively small solubilization enhancement.
  • the lipid cores of the microemulsion droplets in this case medium chain triglyceride, seemed to contribute very little to the solubilization enhancement.
  • Table 9 Microemulsion compositions containing WHI-P131
  • the cumulative solubilization enhancement obtained using a combination of solubilization methods is illustrated in Figure 4.
  • the overall enhancement appears to be additive.
  • WHI-P 131 from its free base to its chloride salt form
  • a fifty fold increase in solubility was achieved raising the drug concentration from 0.025 mg/ml to 1.2 mg/ml.
  • 20%o of PEG300 to the vehicle
  • the drug concentration further increased to 2.2 mg/ml.
  • an incorporation of 3%> of PEG200-DPPE to the cosolvent vehicle brought the drug solubilization to 4.7mg/ml, which corresponds to a total solubilization enhancement of 190 fold.
  • a microemulsion formulation instead a cosolvent/micellar solution was used, one can reached a total solubilization enhancement of 110 fold.
  • WHI-P131 drug containing solution 68 mg of WHI-P131 CI " was dissolved in 4 ml of the above propylene glycol solution and 0.6 ml DI water. This drug mixture was heated at 70°C for 10 min until all the WHI-P131 was dissolved and the solution was yellow and clear. This drug solution was mixed into 27.95 ml of DI water dropwise. The diluted solution was yellow and clear. This drug solution was filtered through 0.2 ⁇ m filter under a laminar flow hood for sterilization. The filtrate was collected in a liquid scintillation vial. The WHI-P 131 concentration in the solution was 1.97 mg/ml. The composition of the solution was:
  • WHI-P131 220 mg was dissolved in 15.7 ml of the above microemulsion. The mixture was stirred and heated at 70°C for 30 min or until all solids were dissolved. WHI-P 131 concentration in this drug microemulsion was 14 mg/ml.
  • Blood samples were obtained from the ocular venous plexus by retroorbital venupuncture prior to and at 3, 5, 10, 15, 30, 45 minutes, and 1, 2, 4, and 8 hours after administration of WHI-P 131. All collected blood samples were heparinized and centrifuged at 7,000 g for 10 min in a microcentrifuge to obtain plasma. The plasma samples were stored at -20°C until analysis. Aliquots of plasma were used for extraction and HPLC analysis.
  • Pharmacokinetic modeling and parameter calculations were carried out using the software, WinNonlin Program, Version 2.0.
  • An appropriate pharmacokinetic model was chosen on the basis of lowest weighted squared residuals, lowest Schwartz criterion, lowest Akaike's Information Criterion value, lowest standard errors of the fitted parameters, and dispersion of the residuals.
  • the elimination half-life was estimated by linear regression analysis of the terminal phase of the plasma concentration profile.
  • the area under the curve (AUC) was calculated by the trapezoidal rule between first (0 h) and last sampling time plus C/k, where C is the concentration of last sampling and k is the elimination rate constant.
  • Systemic clearance (CLs) was determined by dividing the dose by the AUC.
  • Statistical analysis was performed using the Instat program, 3.0. The significance of differences between pharmacokinetic parameters was analyzed using two-tailed t test, and P values ⁇ 0.05 were considered significant.
  • HPLC system consisted of a Hewlett Packard series 1100 equipped with an automated electronic degasser, a quaternary pump, an autosampler, an automatic thermostatic column compartment, diode array detector and a computer with a Chemstation software program for data analysis.
  • a 250 x 4 mm Lichrospher 100, RP-18 (5 ⁇ m) analytical and a 4 x 4 mm Lichrospher 100, RP-18 guard columns were obtained from Hewlett Packard Inc.
  • Acetonitrile/water containing 0.1 % of trifluoroacetic acid and 0.1%o triethylamine (28:72, v/v) was used as the mobile phase.
  • the wavelength of detection was set at 340 nm. Peak width, response time and slit were set at >0.03 min, 0.5 s and 8 nm, respectively.
  • the cells were maintained as monolayer cultures in 75- or 150- cm flask in Eagle's essential medium supplemented with 20% fetal calf serum (Hamawy et. al., 1995, Cellular Signalling 7:535-544).
  • RBL- 2H3 cells were sensitized with monoclonal anti-DNP IgE antibody (0.24 mg/ml) for lhour at 37 °C in a 48-well tissue culture plate.
  • RBL-2H3 cells were allowed to adhere to the plate. Unbound IgE was removed by washing the cells with phosphate buffered saline.
  • mice were sensitized with 2 mg BSA in 200 ⁇ l aluminum hydroxide gel (Reheis Inc., Berkeley, NJ), which induces the production of IgE response to the presented antigen.
  • anaphylactic shock was induced by the i.v. injection of the animals with 200 ⁇ g BSA. Mice were continuously monitored for 3 hours for signs of anaphylaxis.
  • mice Male Balb/c mice (6-8 weeks old) were purchased from Charles River Laboratories (Wilmington, MA). Breeder pairs of JAK3-null mice (Nosaka et. al., 1995) were obtained from Dr. J. Ihle (St. Jude Children's Research Hospital, Memphis, TN). Animals were caged in groups of five in a pathogen free environment in accordance with the rules and regulations of U. S. Animal Welfare Act, and National Institutes of Health (NIH). Animal care and the experimental procedures were carried out in agreement with institutional guidelines. Study We compared the pharmacokinetics of the lead micellar microemulsion formulations of WHI-P 131. The WHI-P 131 plasma concentration- time curves following i.v.
  • Example 15 Mast cell inhibitory "anti-allergic" activity of formulated WHI- PI 31 in vitro.
  • FIG. 6 Micellar solution and microemulsion formulations of WHI-P131 were active.
  • Figure 6 shows the mast cell inhibitory "anti-allergic" activity of these formulations in vitro.
  • Mast cell degranulation ⁇ -hexosaminidase release, % of total
  • Unformulated WHI- P131 has been previously shown to prevent mast cell degranulation and release of preformed granule-associated ⁇ -hexosaminidase in a dose-dependent fashion with near to complete inhibition at >30 ⁇ M (Malaviya R et al., Targeting Janus kinase 3 in mast cells prevents immediate hypersensitivity reactions and anaphylaxis. J Biol Chem., 1999, 274, 27028-38). As shown in Figure 6, both formulations were as effective as unformulated WHIP131 in DMSO. Virtually complete inhibition of mast cell function was achieved at a WHI-P131 concentration of 30 ⁇ M.
  • Example 16 In vivo anti-allergic activity formulated WHI-P131.
  • mice were first injected with BSA in an aluminum hydroxide gel to trigger a BSA-specific IgE response. Ten days later, these BSA-sensitized mice were rechallenged with this antigen to induce anaphylaxis. Only one of 20 (5%) saline treated control mice and 4 of 25 (16%>) micelle vehicle (0% WHI-P131) treated control mice did not develop fatal anaphylaxis (Table 10). The remainder of these control mice (i.e., 40 of 45) developed anaphylaxis and died within 45 min after antigen challenge. In contrast, 7 of 10 (70 %) BSA-sensitized mice that were treated with WHI-P131 (micellar formulation) prior to antigen challenge survived without any signs of anaphylaxis, (PO.05 by log-rank test).
  • Table 10 Protective activity of the WHI-P131 Micellar Formulation against Active Anaphylaxis in Mice.
  • mice were sensitized with 100 mg/kg bovine serum albumin in 200 ⁇ l of the adjuvant aluminum hydroxide gel (Reheis Inc., Berkeley, NJ), which favors the production of IgE in response to the presented antigen.
  • mice were treated with two doses of WHI-P131 formulations (50 mg/kg) or vehicle intraperitoneally 10 min before and 10 min after an intravenous injection of the 10 mg/kg BSA. Mice were continuously monitored for 3 hours for signs of anaphylaxis and the mice surviving the anaphylactic reaction were sacrificed.
  • Figure 6 shows effects of WHI-P131 formulations on IgE receptor/Fc epsilon RI- mediated mast cell degranulation.
  • RBL-2H3 cells were sensitized with monoclonal anti-DNP IgE, treated with WHI-P131 formulations or vehicle control compounds for lh, and then challenged with 20 ng/ml DNP-BSA for 30 min.

Abstract

Pharmaceutical compositions for parenteral administration of poorly soluble quinazoline compounds in the form of microemulsions or micellar solutions are described. The compositions are useful in treating patients suffering from cancer or having allergic reactions.

Description

QUINAZOLINE FORMULATIONS AND THERAPEUTIC USE THEREOF
This application is based on, and claims priority to, U.S. provisional patent application number 60/125,147 filed on 19 March 1999.
Field of the Invention
This application relates to new formulations for poorly water soluble quinazoline compounds and therapeutic methods for the treatment of cancers and treatment of allergic disorders by administering quinazoline formulations.
Background of the Invention
Quinazoline compounds have been suggested as useful compounds in the treatment of cell growth and differentiation characterized by activity of the human epidermal growth factor receptor type2 (HER2). See, for example, Myers etal., U.S. Patent No. 5,721,237. Some quinazoline derivatives have been suggested as useful as anti-cancer agents for the treatment of specific receptor tyrosine kinase-expressing cancers, especially those expressing epithelial growth factor (EGF) receptor tyrosine kinase. See, for example, Barker et. al., U.S. Patent No. 5,457,105. It is generally taught that quinazolines exert their anti-tumor effects via tyrosine kinase inhibition. However, while some quinazoline compounds inhibit the growth of brain tumor cells, others with equally potent tyrosine kinase inhibitory activity fail to do so (Naria etal., 1998, Clin.Cancer Res. 4:1405-1414; Naria etal., 1998, Clin. Cancer Res. 4:2463-2471).
Delivery of these quinazoline compounds to the treatment site is complicated by the fact that many quinazoline compounds are poorly water soluble. This is especially troublesome for aqueous intravenous delivery vehicles. These delivery vehicles are often unable to provide an effective dose of the poorly water soluble quinazoline compound to the treatment site.
Thus, there is a need for water soluble quinazoline formulations that are capable of delivering the quinazoline compounds to the treatment site without loss of biological activity. Novel water soluble quinazoline formulations may provide potent new treatment options for disorders such as cancers. Summary of the Invention
A series of water soluble quinazoline formulations were prepared and analyzed for therapeutic activities, including anti-cancer activities, particularly against JAK3 receptor. The invention provides novel water soluble quinazoline formulations, as disclosed below, as well as therapeutic methods utilizing these formulations.
One aspect of the invention is a pharmaceutical composition comprising a dialkoxyquinazoline compound, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable non-topic lipid based carrier, diluent or vehicle.
Another aspect of the invention is a method of administering a dialkoxyquinazoline compound to a mammal, the method includes combining the dialkoxyquinazoline compound with a pharmaceutically acceptable lipid-based vehicle to form a pharmaceutical composition and administering the pharmaceutical composition to the mammal.
Another aspect of the invention is a pharmaceutical composition including a dialkoxyquinazoline compound in a salt form, PEG phospholipids and a cosolvent system.
Another aspect of the invention is a method of administering a dimethoxyquinazoline compound to a mammal. The method includes providing a pharmaceutical composition including dimethoxyquinazoline compound in the salt form, PEG phospholipids, a cosolvent system, and administering the pharmaceutical composition to the mammal.
Brief Description of the Drawings
Figure 1 is a graph showing the solubility of WHI-P131 chloride as a function of PEG 300 and PEG 200 concentration.
Figure 2 is a graph showing solubility of WHI-P131 chloride as a function of PEG2000-DPPE concentration. Figure 3 is a ternary phase diagram showing the location of a single phase microemulsion region.
Figure 4 is a flow diagram of the cumulative solubilization enhancement of WΗI-P131 with the formulations of the invention. Figure 5 is a graph showing the plasma concentration-time curves following i.v. bolus injection of WHI-P131 formulations of the invention in mice.
Figure 6 is a graph showing mast cell inhibitory "anti-allergic" activity of the formulations of the invention in vitro.
Detailed Description of the Invention Definitions:
The terms "quinazoline", "quinazoline compound", and "quinazoline derivative" are used interchangeably in this application to mean compounds of formula I.
All scientific and technical terms used in this application have meanings commonly used in the art unless otherwise specified. As used in this application, the following words or phrases have the meanings specified.
Halo is fluoro, chloro, bromo, or iodo. Alkyl, alkanoyl, etc., denote both straight and branched groups; but reference to an individual radical such as "propyl" embraces only the straight chain radical, a branched chain isomer such as "isopropyl" being specifically referred to. (Cι-C4)alkyl includes methyl, ethyl, propyl, isopropyl, butyl, iso-butyl, and sec-butyl; (Q-C )alkoxy includes methoxy, ethoxy, propoxy, isopropoxy, butoxy, iso-butoxy, and sec-butoxy; and (Q- C4)alkanoyl includes acetyl, propanoyl and butanoyl.
As used herein, "pharmaceutically acceptable carrier" means any material which, when combined with the compound of the invention, allows the compound to retain biological activity, such as the ability to potentiate antibacterial activity of mast cells and macrophages. The term "conjugate" means a compound formed as a composite between two or more molecules. More specifically, in the present invention, the quinazoline derivative is bonded, for example, covalently bonded, to cell-specific targeting moieties forming a conjugate compound for efficient and specific delivery of the agent to a cell of interest. The phrase "targeting moiety" means a molecule which serves to deliver the compound of the invention to a specific site for the desired activity. Targeting moieties include, for example, molecules that specifically bind molecules on a specific cell surface. Such targeting moieties useful in the invention include anti-cell surface antigen antibodies. Cytokines, including interleukins and factors such as granulocyte/macrophage stimulating factor (GMCSF) are also specific targeting moieties, known to bind to specific cells expressing high levels of their receptors.
The term "prodrug moiety" is a substitution group which facilitates use of a compound of the invention, for example by facilitating entry of the drug into cells or administration of the compound. The prodrug moiety may be cleaved from the compound, for example by cleavage enzymes in vivo. Examples of prodrug moieties include phosphate groups, peptide linkers, and sugars, which moieties can be hydrolyzed in vivo. The term "inhibit" means to reduce by a measurable amount, or to prevent entirely.
The term "to treat" means to inhibit or block at least one symptom that characterizes a pathologic condition, in a mammal threatened by, or afflicted with, the condition.
Quinazoline Formulations
The invention is directed towards formulations for delivery of an effective amount of quinazoline to a treatment site. The formulations relate to pharmaceutical compositions that include a quinazoline compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable, lipid— based vehicle or delivery system. Preferably, the vehicle or delivery system of the quinazoline composition is a nontoxic delivery system or vehicle for parenteral administration. The formulations disclosed enhance the water solubility of quinazoline compounds without loss of biologic activity of the quinazoline compound at the treatment site.
Quinazoline Compounds
Quinazoline compounds include quinazolines having the formula:
Figure imgf000006_0001
where:
Ra is hydrogen; halo; hydroxy; mercapto; ( -C )hydroxyalkyl, methylenedioxy, ethylenedioxy, benzyloxy,OCF3> SCF3ι SO3H, SO2F, SO2NR2R3 in which R2 is hydrogen or (C[-C )alkyl and R3 is hydrogen, (C]-C4)alkyl, or phenyl, NR2R4 in which R2 is as defined above and R4 is phenyl, or Ra a group of the formula
Figure imgf000007_0001
in which R5 and R are each, independently, hydrogen, ( -C4)alkyl, or (Cι-C4)perfluoroalkyl, and R7 is hydrogen, halo, hydroxy, ( -C4)alkyl, (C\- C )alkoxy, (Cι-C )hydroxyalkyl, or N(R )2 in which R is as defined above; n is an integer of 1-4;
Rb is each, independently, hydrogen; halo; hydroxy; mercapto; ( - C4)alkyl, (C[-C4)alkoxy, (Cι-C4)thioalkyl, (Cι-C )hydroxyalkyl, nitro, cyano, methylenedioxy, ethylenedioxy, COCH3, CF3;, OCF3; SCF3; COOH; SO3H; SO2F; phenyl or phenyl substituted by a group selected from halo, hydroxy, mercapto, (Q- C4)alkyl, (Cι-C4)alkoxy, (Cι-C4)thioalkyl, (Cj-C4)hydroxyalkyl, amino, nitro, cyano, CF3, COOH, SO3H, SO2NR2R3 in which R2 and R3 are as defined below, and SO2F;
Ra is also benzyloxy substituted on the phenyl portion by a group defined above, NR2R3 in which R2 is H or (Cι-C4)alkyl and R3 is H, (Cι-C4)alkyl, phenyl or phenyl substituted by a group as defined above;
R1 is (C]-C4)alkyl, preferably methyl, or a pharmaceutically acceptable salt thereof, such as an acid addition salt.
Preferred quinazoline compounds useful in the treatment of tumors are described more fully below and particularly in the Examples.
Delivery System
The quinazoline compounds of the invention are useful as pharmaceutical compositions prepared with a therapeutically effective amount of a quinazoline compound and a pharmaceutically acceptable carrier. The quinazoline formulations of the invention can be administered to a mammalian host, such as a human patient in a variety of forms adapted to the chosen route of administration, i.e., orally or parenterally, by intravenous, intramuscular, transdermal or subcutaneous routes. The present invention is especially suitable for parenteral administration, particularly intravenous administration. The amount of quinazoline compounds in such therapeutically useful formulations is such that an effective dosage level will be obtained.
The quinazoline formulations may be administered intravenously or intraperitoneally by infusion or injection. Solutions of the quinazoline compounds can be prepared in water, optionally mixed with a nontoxic surfactant. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, triacetin, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
The pharmaceutical dosage forms suitable for injection or infusion can include sterile aqueous solutions or dispersions or sterile powders including the quinazoline compounds which are adapted for extemporaneous preparation of sterile injectable or infusible solutions or dispersions, or encapsulated in liposomes. Preferably, the vehicle is a micellar solution, microemulsion or mixtures thereof. In all cases, the ultimate dosage form must be sterile, fluid and stable under the conditions of manufacture and storage. The liquid carrier or vehicle can be a solvent or liquid dispersion medium comprising, for example, water, ethanol, a polyol (for example, glycerol, propylene glycol, liquid polyethylene glycols, and the like), vegetable oils, nontoxic glyceryl esters, and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the formation of liposomes, by the maintenance of the required particle size in the case of dispersions, such as microemulsions, or by the use of surfactants, such as micellar solutions. Micellar Systems
Micelles are composed of aggregates consisting of generally 50 or more surfactant molecules. Micelles form in aqueous solutions at surfactant concentrations above the critical micellar concentration (CMC). Micelles have the ability to solubilize lipophilic or amphiphilic compounds. Thus, micellar systems can be used to enhance the solubility of poorly water soluble substances, such as some quinazoline compounds.
As illustrated in the Examples, a number of micellar solutions are good solubilizing vehicles for poorly water soluble quinazoline compounds. Micellar system formulations include a quinazoline compound, one or more surfactants, and a carrier.
Surfactants such as PEGylated phosphatidylethanolamines (1,2- Dipalmitoyl-sn-Glycero-3-Phosphoethanolamine-N-[Poly(ethylene glycol) 5000] and 1 ,2-Dipalmitoyl-sn-Glycero-3-Phosphoethanolamine-N-[Poly(ethylene glycol) 2000]) are effective in enhancing the solubilization of quinazoline compounds. The solubilization enhancement, as represented by the amount of solubilized quinazoline compound (in milligram) per gram of surfactant varies with the type of surfactant used and depends on the hydrophobic chain length and polyoxyethylene number of the PEGylated phospholipid. Preferred PEGylated phospholipids include PEG2000-DPPE® and PEG5000-DPPE® and are commercially available from Avanti Polar-Lipids Inc., (Alabaster, AL.).
The micellar solution may include a second surfactant such as, block copolymers of ethylene oxide and propylene oxide alone or in addition to the PEGylated phosphatidylethanolamine surfactant. Preferred block copolymers of ethylene oxide and propylene oxide include; Pluronic F-77, Pluronic F-87, and Pluronic F-88 and are commercially available form BASF Corp., (Mount Olive, NJ.)
The micellar solution may include a carrier. A preferred carrier is propylene glycol such as 1,2-propanediol. Microemulsion Systems
Microemulsions are thermodynamically stable, transparent, dispersions of water and oil, stabilized by an interfacial film of surfactant molecules. Microemulsions are characterized by their submicron particle size of 0.1 μm or below. Microemulsions and self-emulsifying drug delivery systems (SEDDS) can be used to enhance the solubility of poorly water soluble substances, such as some quinazoline compounds.
As illustrated in the Examples, a number of microemulsion solutions are good solubilizing vehicles for poorly water soluble quinazoline compounds. Microemulsion system formulations include a quinazoline compound, one or more surfactants, and a carrier.
The microemulsion solution may include one or more surfactants. These include block copolymers of ethylene oxide and propylene oxide. Preferred block copolymers of ethylene oxide and propylene oxide include; Pluronic F-77, Pluronic F-87, and Pluronic F-88 and are commercially available from BASF Corp., (Mount Olive, NJ.)
Other surfactants useful in microemulsion solutions include, ethoxylated castor oil such as Cremophor® EL castor oil commercially available from BASF Corp., (Mount Olive, NJ,) and purified soy bean phospholipid or lecithins such as phosphatidylcholine or Phospholipon® 90G commercially available from American Lecithin (Oxford, CT.)
The microemulsion solution may include one or more a carriers. Preferred carriers include, propylene glycol such as 1 ,2-propanediol, and medium chain triglycerides and monoglycerides such as, triglycerides of caprylic/capric acid such as, Captex® 355, Captex® 350 and Captex® 200 commercially available from Abitec Corp., (Columbus, OH.)
The prevention of the action of microorganisms in the formulation can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, buffers or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.
Sterile injectable solutions are prepared by incorporating the quinazoline compounds in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filter sterilization. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and the freeze drying techniques, which yield a powder of the active ingredient plus any additional desired ingredient present in the previously sterile- filtered solutions.
Methods of Treatment The quinazoline formulations of the invention are useful for the treatment of animals, including humans. In particular, these quinazoline formulations have been found to be potent inhibitors of tumor cell proliferation and survival, and effective to induce apoptosis of malignant cells. Compounds of the invention have surprisingly been found to be effective for inducing apoptosis and/or cytotoxicity of leukemia cells. In particular, 4-(4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline compounds (WHI-P131) of the invention have been found to effectively induce apoptosis in multi-drug resistant leukemia. WHI-P131 is also a potent inhibitor of Janus kinase 3 (JAK 3) and shows considerable clinical potential for treatment of hematologic malignancies as well as allergic disorders. A preferred compound for the treatment of multi-drug resistant leukemia is 4-(3'-bromo-4'-hydroxyphenyl)amino-6,7- dimethoxyquinazoline. Compounds of the invention that are particularly useful for treating leukemia include:
4-(3',5'-dibromo-4'-methylphenyl)amino-6,7-dimethoxyquinazoline, 4-(2',4',6'-tribromophenyl)amino-6,7-dimethoxyquinazoline, 4-(2',3',5',6'-tetrafluoro-4'-bromophenyl)amino-6,7- dimethoxyquinazoline,
4-(4'-fluorophenyl)amino-6,7-dimethoxyquinazoline, 4-(3'-fluorophenyl)amino-6,7-dimethoxyquinazoline, 4-(2'-fluorophenyl)amino-6,7-dimethoxyquinazoline, 4-(4'-trifluoromethylphenyl)amino-6,7-dimethoxyquinazoline, 4-(2'-trifluoromethylphenyl)amino-6,7-dimethoxyquinazoline, and
4-(3',5'-bis-trifluoromethylphenyl)amino-6,7-dimethoxyquinazoline.
Compounds of the invention that are particularly useful for treating breast tumors include:
4-(3'-bromophenyl)amino-6,7-dimethoxyquinazoline, 4-(3',5'-dibromo-4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline,
4-(3'-chloro-4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline, 4-(3',5'-bis-trifluoromethylphenyl)amino-6,7-dimethoxyquinazoline, 4-(2,,3',5',6'-tetrafluoro-4'-bromophenyl)amino-6,7- dimethoxyquinazoline, 4-(4'-fluorophenyl)amino-6,7-dimethoxyquinazoline,
4-(3 '-fluorophenyl)amino-6,7-dimethoxyquinazoline, and 4-(2'-fluorophenyl)amino-6,7-dimethoxyquinazoline.
Useful dosages of the quinazoline compounds can be determined by comparing their in vitro activity, and in vivo activity in animal models. Methods for the extrapolation of effective dosages in mice, and other animals, to humans are known to the art; for example, see U.S. Pat. No. 4,938,949.
The amount of the quinazoline compounds required for use in treatment will vary not only with the particular salt selected but also with the route of administration, the nature of the condition being treated and the age and condition of the patient and will be ultimately at the discretion of the attendant physician or clinician.
In general, however, a suitable dose will be in the range of from about 0.5 to about 100 mg/kg, e.g., from about 10 to about 75 mg/kg of body weight per day, such as 3 to about 50 mg per kilogram body weight of the recipient per day, preferably in the range of 6 to 90 mg/kg/day, most preferably in the range of 15 to 60 mg/kg/day.
The quinazoline compounds are conveniently administered in unit dosage form; for example, containing 5 to 1000 mg, conveniently 10 to 750 mg, most conveniently, 50 to 500 mg of active ingredient per unit dosage form.
Ideally, the quinazoline compounds should be administered to achieve peak plasma concentrations of from about 0.5 to about 75 μM, preferably, about 1 to 50 μM, most preferably, about 2 to about 30 μM. This may be achieved, for example, by the intravenous injection of a 0.05 to 5% solution of the quinazoline compounds. Desirable blood levels may be maintained by continuous infusion to provide about 0.01-5.0 mg/kg/hr or by intermittent infusions containing about 0.4- 15 mg/kg of the quinazoline compounds.
The quinazoline compounds may conveniently be presented in a single dose or as divided doses administered at appropriate intervals, for example, as two, three, four or more sub-doses per day. The sub-dose itself may be further divided, e.g., into a number of discrete loosely spaced administrations.
Targeting quinazolines to cells
In a preferred embodiment, the quinazoline compound is targeted to cells where treatment is desired, for example, to leukemia cells, to breast cells, or to other tumor cells. The compound is targeted to the desired cell by conjugation to a targeting moiety that specifically binds the desired cell, thereby directing administration of a conjugated molecule. Useful targeting moieties are ligands which specifically bind cell antigens or cell surface ligands, for example, antibodies against the B cell antigen, CD 19 (such as B43) and the like.
To form the conjugates of the invention, targeting moieties are covalently bonded to sites on the quinazoline compound. The targeting moiety, which is often a polypeptide molecule, is bound to compounds of the invention at reactive sites, including NH , SH, CHO, COOH, and the like. Specific linking agents are used to join the compounds. Preferred linking agents are chosen according to the reactive site to which the targeting moiety is to be attached.
Methods for selecting an appropriate linking agent and reactive site for attachment of the targeting moiety to the compound of the invention are known, and are described, for example, in Hermanson, et al., Bioconjugate Techniques, Academic Press, 1996; Hermanson, et al., Immobilized Affinity Ligand Techniques, Academic Press, 1992; and Pierce Catalog and Handbook, 1996, pp. T155-T201.
Administration of quinazoline formulations
According to the invention, quinazoline compounds may be administered prophylactically, i.e., prior to onset of the pathological condition, or the quinazoline compounds may be administered after onset of the reaction, or at both times.
EXAMPLES
The invention may be further clarified by reference to the following Examples, which serve to exemplify some of the preferred embodiments, and not to limit the invention in any way.
Example 1 Synthesis of Quinazoline Derivatives
All chemicals were purchased from the Aldrich Chemical Company, Milwaukee, Wisconsin, and were used directly for synthesis. Anhydrous solvents such as acetonitrile, methanol, ethanol, ethyl acetate, tetrahydrofuran, chloroform, and methylene chloride were obtained from Aldrich as sure seal bottles under nitrogen and were transferred to reaction vessels by cannulation. All reactions were carried out under a nitrogen atmosphere. The key starting material, 4-chloro-6,7-dimethoxy quinazoline, was prepared according to published procedures (Nomoto, et al., 1990, Chem. Pharm. Bull, 38:1591-1595; Thomas, C. L., 1970, m.-Catalytic Processes and Proven Catalysts, Academic Press, New York, NY) as outlined below in Scheme 1. Specifically, 4,5-dimethoxy-2-nitrobenzoic acid (compound 1) was treated with thionyl chloride to form acid chloride, followed by reacting with ammonia to yield 4,5-dimethoxy-2-nitrobenzamide (compound 2). Compound 2 was reduced with sodium borohydride in the presence of catalytic amounts of copper sulphate to give 4,5-dimethoxy-2-aminobenzamide (compound 3), which was directly refluxed with formic acid to yield 6,7-dimethoxyquinazoline-4(3H)-one (compound 4). Compound 4 was refluxed with phosphorus oxytrichloride to give 4~chloro-6,7- dimethoxyquinazoline (compound 5) in good yield.
Figure imgf000014_0001
Figure imgf000014_0002
Scheme 1
Substituted quinazoline derivatives were prepared by the condensation of 4-chloro-6,7-dimethoxy quinazoline with substituted anilines as outlined below in Scheme 2:
Figure imgf000015_0001
R = substituent; n = number
Scheme 2
Specifically, a mixture of 4-chloro-6,7-dimethoxy quinazoline (448 mg, 2 mmols) and the substituted aniline (2.5 mmols) in EtOH (20 ml) was heated to reflux. After refluxing for 4-24 hours, an excess amount of Et3N was added, and the solvent was concentrated to give the crude product which was recrystalized from DMF.
As discussed above, the novel hydroxy-substituted quinazoline derivatives of the invention were created by reacting the appropriate substituted anilines with the key starting material, 4-chloro-6,7-dimethoxy quinazoline.
Physical Characteristics: Melting points are uncorrected. Η NMR spectra were recorded using a Varian Mercury 300 spectrometer in DMSO-d6 or CDC13. Chemical shifts are reported in parts per million (ppm) with tetramethylsilane (TMS) as an internal standard at zero ppm. Coupling constants (J) are given in hertz and the abbreviations s, d, t, q, and m refer to singlet, doublet, triplet, quartet and multiplet, respectively. Infrared spectra were recorded on a Nicolet PROTEGE 460-IR spectrometer. Mass spectroscopy data were recorded on a FINNIGAN MAT 95, VG 7070E-HF G.C. system with an HP 5973 Mass Selection Detector. UV spectra were recorded on BECKMAN DU 7400 and using MeOH as the solvent. TLC was performed on a precoated silica gel plate (Silica Gel KGF; Whitman Inc). Silica gel (200-400 mesh, Whitman Inc.) was used for all column chromatography separations. All chemicals were reagent grade and were purchased from Aldrich Chemical Company (Milwaukee, Wis) or Sigma Chemical Company (St. Louis, MO). Example 2 Bromine Substituted Quinazoline Compounds
Bromine substituted quinazoline derivatives were synthesized and characterized as discussed above in Example 1. The structures and physical data are shown below:
Bromine Substituted Quinazoline Compounds
Figure imgf000016_0001
Figure imgf000017_0001
Figure imgf000018_0001
4— (3 '-Bromophenyl)-amino-6, 7 -dimethoxyquinazoline (HI-P79)
Yield 84.17%; m.p.246.0-249.0 °C. 1H NMR(DMSO-d6): δ 10.42(br, s, IH, NH), 8.68(s, IH , 2-H), 8.07-7.36(m, 5H, 5, 2', 4', 5', 6'-H), 7.24(s, IH, 8H), 3.98(s, 3H, - OCH3), 3.73(s, 3H, -OCH3); IR(KBr)υmaχ: 3409, 2836, 1632, 1512, 1443, 1243, 1068 cm '; GC/MS m z 361(M++1, 61.8), 360(M+, 100.0), 359(M+ -1, 63.5), 344(1 1.3). 222(10.9), 140(13.7). Anal. (Cι6H14BrN3O2 HC1) C, H, N.
4- (4 '-Bromo-2 '-caboxylphenyl)-amino-6, 7-dimethoxyqιtinazoline(HI-P88)
Yield 92.82 %; m.p. > 300.0 °C. 1H NMR(DMSO-d6 + CF3CO2H) : δ 9.95(d, IH), 8.74(d, IH, Ar-H), 8.30, 8.28(2d, 2H), 7.95(d, IH) , 7.83(s, IH), 4.21(s,3H, -OCH3), 4.15(s,3H, -OCH3). UV(MeOH): 205, 229.0 nm. IR(KBr)υmax : 3444(br), 2737, 1592, 1504, 1443, 1273, 1070 cm '. GC/MS m/z 388(M+ + 1 - OH, 18.08), 387(M+ - OH,100.00), 386(M+ - 1 - OH, 30.84), 385(97.52), 299(4.78). Anal. (C16H14BrN3O2 HC1) C, H, N.
4- (3 ', 5 '-Dibromo-4 '-hydroxylphenyl) -amin o-6, 7-dimeth oxyquinazolin e (HI- P97).
Yield 72.80%; m.p.> 300.0 °C. Η NMR(DMSO-d6): δ 9.71(s, IH, -NH), 9.39(s, IH, -OH), 8.48(s, IH, 2-H), 8.07(s, 2H, 2', 6'-H), 7.76(s, IH, 5-H), 7.17(s, IH, 8-H), 3.94(s, 3H, -OCH3), 3.91(s, 3H, -OCH3). UV(MeOH): 208.0, 210.0, 245.0 , 320.0 nm; IR(KBr)υmax: 3504(br), 3419, 2868, 1627, 1512, 1425, 1250, 1155 cnf '; GC/MS m/z 456(M++1, 54.40), 455(M+, 100.00), 454(M+-1, 78.01), 439(M+-OH, 7.96), 376(M++1-Br, 9.76), 375(M+-Br, 10.91), 360(5.23). Anal. (CI6H,3Br2N3O3) C, H, N.
4-(3 '-Bromo-4 '-methylphenyl)-amino-6, 7-dimethoxy quinazoline (HI-PU1) :
Yield 82.22 %; m.p.225.0-228°C. 1H NMR(DMSO-d6): δ 10.23(s, IH, -NH), 8.62(s, IH, 2-H), 8.06(d, 1H, J 2',6' = 2.1 Hz, 2'-H), 7.89(s, IH, 5-H), 7.71(dd, IH, J 5.6. = 8.7 Hz, J 2.>6. = 2.1 Hz, 6'-H), 7.37(d, IH, J 5.>6. = 8.7 Hz, 5'-H), 7.21(s, IH, 8-H), 3.96(s, 3H, -OCH3), 3.93(s, 3H, -OCH3). UV(MeOH): 204.0, 228.0, 255.0, 320.0 nm. IR(KBr)υmax: 3431, 3248, 2835, 1633, 1517, 1441, 1281, 1155 cm-1. GC/MS m/z 375(M++1, 76.76), 374(M+, 100.00), 373(M+-1, 76.91), 358(M++l-OH, 11.15). 357(1.42), 356(6.31). Anal. (Cι7H16BrN3O2.HCl) C, H, N. 4-(2,,5'-Dibromophenyl)-amino-6,7-dimethoxyquinazoline (HI-P112): Yield 70.05%; m.p.>300.0 °C. Η NMR(DMSO-d6): δ 1 1.51(s, IH, -NH), 8.76(s, IH, 2-H), 8.21(s, IH, 5-H), 7.81(d, IH, J4> 6- = 2.4 Hz, 6'-H), 7.75(d, IH, J3vr = 8.7 Hz, 3'-H), 7.55(dd, IH, J 4.,6- = 2.4 Hz, J 3 ,. = 8.7 Hz, 4'-H), 7.33(s, IH, 8-H), 3.98(s, 3H, -OCH3), 3.97(s, 3H, -OCH3). UV(MeOH): 208.0, 238.0, 330.0 nm. IR(KBr)υmax: 3444, 2836, 1628, 1510, 1431, 1277, 1070 cm"1. GC/MS m/z 440(M+ +1, 10.12), 439(M+, 7.0), 438(M+-1, 3.63), 360(M++1-Br, 99.42), 359(M+-Br, 20.45), 358(M+- 1-Br, 100.00), 343(20.80) , 299(8.62). Anal. (Cι6Hι3Br2N3O2.HCl) C, H, N.
4— 1(3 '-Bromo-9 '-fluorenone)-2 '-Jamino-6, 7-dimethoxyquinazoline (HI-P119) : Yield 75.23%; m.p.255.0-257.0 °C. 1H NMR(DMSO-d6): δ 8.77(s, IH, -NH), 8.33(s, IH. 2-H), 7.89(s, IH, 5-H), 7.40(s, IH, 8-H), 7.74- 7.26(m, 6H, Ar-H), 4.12(s,3H, - OCH3), 4.1 l(s,3H, -OCH3). UV(MeOH): 205, 229.0 , 251.0, 320.0 nm. IR(KBr)υmax: 3444, 2836, 1628, 1510, 1431, 1277, 1070 cm-1. GC/MS m/z 464(M+ + 2 ,40.81), 463(M++1, 7.56), 462(M+, 27.26), 384(M++2-Br, 69.56), 383(M++1-Br, 35.50), 382(M+-Br, 100.00), 352(10.85), 206(26.73), 191(11.31). Anal. (C23Hι6BrN3O3 HCl) C, H, N.
4- (2 ',3 5 6 '- Tetrafluoro-4 '-bromolphenyl)-amino-6, 7 -dime-thoxy quinazoline
(HI-P144: Yield 78.24%; m.p. 180.0-182.0°C. 1H NMR (DMS O-d6): δ 7.78(s, IH, 2-H), 7.53(s, IH, 5-H), 6.79(s, IH, 8-H), 3.81(s,3H, -OCH3 ), 3.3.79(s,3 H, -OCH3 ). Anal (CiβHio BrF4N3O2.HCl) C, H, N.
4— (3 '-Bromo— 4 '-hydroxylphenyl)-amino-6, 7-dimethoxyquinazoline (HI-P154) :
Yield 89.90%; m.p.233.0-233.5 °C. Η NMR(DMSO-d6): δ 10.08(s, IH, -NH), 9.38(s, IH , -OH), 8.40(s, IH, 2-H), 7.89(d, IH, Jr 6' = 2.7 Hz, 2'-H), 7.75(s, IH, 5- H), 7.55(dd, lH, J5' 6' = 9.0 Hz, J2- 6' = 2.7 Hz, 6'-H), 7.14(s, IH, 8-H), 6.97(d, IH, J 5-.6- = 9.0 Hz, 5'-H), 3.92(s, 3H, -OCH3), 3.90(s, 3H, -OCH3). UV(MeOH): 203.0, 222.0, 250.0, 335.0 nm. IR(KBr)υmax: 3431(br), 2841, 1624, 1498, 1423, 1244 cm"1. GC/MS m/z 378(M+ +2, 90.68), 377(M+ +1, 37.49), 376(M+, 100.00), 360(M+, 3.63), 298(18.86), 282 (6.65). Anal. (Cι6HI4BrN3O3.HCl) C, H, N.
4-[(7'-Bromofluorene)-2 'J-amino-6, 7— dimethoxyquinazoline (HI-P160) :
Yield 73.21 %; m.p. 254.0-256.0 °C. 1H NMR(DMSO-d6): δ 9.69(br, s, IH, -NH), 8.52(s, IH, 2-H), 8.12-7.20(m, 9H, 5, 8,1', 3', 4', 5', 6', 8', 9'-H), 3.99(s,3H, - OCH3), 3.94(s, 3H, -OCH3). UV(MeOH): 208.0, 223.0 , 348.0 nm. IR(KBr)υmax: 3421, 2820, 1624, 1516, 1431, 1294, 1223 cm"1. GC/MS m/z 450(M+ +2, 100), 449(M+ +1, 35), 448(M+,95), 311(25). Anal. (C23H18BrN3O2.HCl) C, H, N.
4-(3,-Bromobenzoyl)-6,7-dimethoxyquinazoline (HI-P164): Yield 81.20%, m.p.258.0-263.0 °C. Η NMR(DMSO-d6): δ 9.25(s, IH, 2-H), 8.14(s, IH, 5-H), 7.92-7.43(m, 4H , 2', 4', 5', 6'-H), 7.40(s, IH, 8-H), 4.1 l(s, 3H, -OCH3), 4.00(s, 3H, -OCH3). UV(MeOH): 203.0, 220.0 ,238.0 nm. IR(KBr)υma : 3432, 1664, 1504, 1431, 1230 cm"1. GC/MS m/z 374(M+ +1, 48.96), 373(M+, 34.93), 372(M+-1 , 47.67), 357(58.74), 343(100.00 ), 293(M+-Br, 31.48), 189(26.27). Anal. (Cι7Hι3BrN2O3) C, H, Br, N.
4-(4'-Bromo-6,-hydroxymethylphenyl)-amino-6,7-dimethoxyquinazoline (HI-
P190): Yield 73.08 %; m.p. 222.0-223.0 °C. 1H NMR(DMSO-d6): δ 11.30(s, IH , -OH), 8.22(s, IH, -NH), 7.77-7.23(m, 5H, 5, 8, 2', 3', 5'-H), 4.49(s, 2H, PhCH2-H), 4.01(s, 3H, -OCH3), 3.90(s, 3H, -OCH3). UV(MeOH): 207.0, 250.0, 332.0 nm. IR(KBr)υmax: 3446, 2829, 2752, 1652, 1560, 1471, 1365, 1280 cm"1. GC/MS m/z 391(M++1, 29.33), 389(M+, 29.82), 360(M+-CH2OH, 50.76), 358(52.39), 31 1(18.33), 280(43.20), 206(62.80), 191(100.00). Anal. (Cι7H16BrN3O3.HCl) C, H, N.
4— (2 ',3 '-Dibromo-4 '-methylphenyl)—amino-6, 7-dimethoxyquinazoline (HI— P210):
Yield 81.24%, mp 233.0-236.0 °C, Η NMR(DMSO-d6):δ 8.55(s, IH, -NH), 8.08(s, IH, 2-H), 7.33-7.17(m, 4H, 5,8,5',6'-H), 3.89(s, 6H, -OCH3), 2.35(s,3H, - CH3). UV(MeOH): 207.0, 232.0, 247.0 , 330.0 nm. IR υmax (KBr) : 3448, 2840, 1629, 1580, 1525, 1420, 1281 cm"1. GC/MS m/z 454(M++1, 4.45) , 453(M+, 1 1.31), 452(M+-1,4.45), 375(20.36), 374(97.59), 373( 23.55), 372(100.00), 358 (19.61), 356 (18.43). Anal. (C]7HI5 Br2N3O2.HCl) C, H, N.
4— (2',5'—Dibromo- '- methylphenyl)- amino- 6, 7-dimethoxyquinazoline (HI— P211): Yield 83.50 %; m.p. 282.0-284.0°C. 1H NMR(DMSO-d6) : δ 11.30(s, IH, -NH), 8.58(s, IH, 2-H ), 8.00(s, IH, 5-H), 7.65(s, IH, 6'-H), 7.60(s, IH, 3'-H), 7.13(s, IH, 8-H), 3.79(s, 3H, -OCH3), 3.78(s, 3H, -OCH3), 2.29(s, 3H, -CH3). UV(MeOH): 207.0, 239.0, 330.0 nm. IR(KBr)υmax: 3442, 2620, 1631, 1580, 1514, 1380, 1280 cm"1. GC/MS m/z 454(M++1, 5.86), 453(M+, 16.16), 452(M+-1, 5.35), 374(92.12), 373(23.66), 372(100.00), 358(17.68), 356(17.35). Anal. (C17H15Br2N3O2.HCl) C, H, N.
4-(3 ',5'-Dibromo-4'-methylphenyl)-amino-6, 7-dimethoxyquinazoline (HI-
P212): Yield 83.47 %; m.p. 275.0-279.0°C. Η NMR(DMSO-d6): δ 11.30(s, IH, -NH), 8.58(s, IH, 2-H), 8.35(s, IH, 5-H), 7.24(s, 2H, 2', 6'-H), 7.13(s, IH, 8-H), 3.91(s, 3H, -OCH3), 3.88(s, 3H, -OCH3), 2.3 l(s, 3H, -CH3). UV(MeOH): 237.0, 307.0, 319.0 nm. IR(KBr)υmax : 3471, 3434, 2640, 1633, 1580, 1504, 1420, 1281 cm"1. GC/MS m/z 454(M++1, 5.34), 453(M+, 16.05), 452(M+-1, 5.87), 374(99.02), 373(26.20), 372(100.00), 358(20.39), 356(19.98), 32(8.29), 314(8.49), 206(19.02). Anal. (C17H15Br2N3O2 HCl) C, H, N.
4— (2 '-Fluoro— 4 '-bromophenyl)-amino—6, 7— dimethoxyquinazoline (HI-P214) :
Yield 77.21 %; m.p. 243.0-245.0°C. 1H NMR(DMSO-d6): δ 8.57(s, IH, 2-H), 7.91(s, IH, 5-H), 7.57(d, IH, 3'-H), 7.34 (m, 2H, 5\6'-H), 7.07(s, IH, 8-H), 3.78(s, 3H, -OCH3), 3.77(s, 3H, -OCH3). UV(MeOH): 204.0, 215.0, 250.0, 330.0 nm. IR(KBr)υmax: 3431, 2629, 1633, 1580, 1511, 1420, 1278 cm"1. GC/MS m z 379(M++1, 34.39) , 378(M+, 21.33), 377(M+-1, 39.08), 360(62.05), 359(31.58), 358(62.57), 357(19.81), 299(19.31), 298(100.00), 282(17.88), 240(28.76). Anal. (Cι6H13BrFN3O2 HCl) C, H, N.
4-(2',4',6'-Tribromophenyl)amino-6,7-dimethoxyquinazoline (HI-P222):
Yield 54.86 %; m.p.250.0-255.0 °C. 1H NMR(DMSO-d6): δ 8.00(s, IH, 2-H), 7.89(s, 2H, 3',5'-H), 7.74(s, IH, 5- H), 7.01(s, IH, 8-H), 3.87(s, 3H, -OCH3), 3.86(s, 3H, -OCH3). UV(MeOH): 209.0, 236.0, 333.0 nm. IR(KBr)υmax: 3417, 2838, 1625, 1514, 1429, 1276, 1073 cm"1. GC/MS m/z 519(MT+1, 18.12), 518(M+, 17.30), 517(M+-1, 16.63), 439(M++1-Br, 99.42), 438(M+-Br, 95.45), 437(M+-1-Br, 100.00), 359(20.80) , 358(18.62), 357(19.32), 281(88.98), 207(15.42). Anal. (C16H,2Br3N3O2 HCl) C, H, N.
4- (2 ',6 '-Dibromo-4'-methylphenyl)-amino-6, 7-dimethoxyquinazoline (HI- P241): Yield 79.47 %, m.p. 235.0-237.0 °C. 1H NMR(DMSO-d6): δ 9.77(s, IH, -HN), 8.20 (s, IH, 2- H ), 7.87(s, IH, 8-H), 7.61(s, 2H, 3', 5' -H), 7.15(s, IH, 5-H), 3.93(s, 6H, -OCH3). UV( MeOH): 208.0, 245.0, 318.0, 339.0 nm. IR(KBr)υmax: 3241, 2839, 2783, 1635, 1580, 1514, 1420, 1360, 1281 cm"1. GC/MS m/z 454(M++1 ,7.86), 453(M+, 56.16), 452(M+-1, 15.30), 374(95.12), 373(18.66), 372(100.00), 358(29.64), 356(19.36). Anal. (Cι7H15Br2N3O2 HCl) C, H, N.
4- (4 '-Bromophenyl)-amino-6, 7-dimethoxyquinazoline (HI-P260) :
Yield 75.28%. m.p.270.0-272.0 °C. 1H NMR(DMSO-d6) : δ 1 1.30(s, IH. -NH), 8.85(s, IH , 2-H), 8.27(s, IH, 5-H), 7.70(s, 4H, 2',3',5',6'-H), 7.32(s, IH, 8H), 4.02(s,3H, -OCH3). 4.00(s,3H, -OCH3). UV(MeOH):204.0, 218.0, 252.0, 335.0 nm. IR(KBr) υmax: 3431, 3034, 2636,1635, 1589,1514, 1435, 1284 cm"1. GC/MS m z 361 ( M++l,74.00) , 360( M+, 100.00), 359( M+-l,72.00), 358( M+-2, 95.00), 329 (3.20 ), 301 ( 13.0 ), 281 ( 21.0 ), 207( 38.0 ). Anal. (C16H14BrN3O2.HCl) C, H, N. 4- (2 '-Bromophenyl)-amino-6, 7-dimethoxyquinazoline (HI-P261) :
Yield 71.94%; m.p.241.0-243.0 °C. 1H NMR( DMSO-d6) : δ 11.67 ( d, IH, -NH), 8.79 ( s, IH , 2-H ), 8.32 ( s, IH, 5-H ), 7.86-7.38 ( m, 4H, 3', 4', 5',6'-H ), 7.40 ( s, IH, 8H ), 4.01 ( s,6H, -OCH3 ). UV(MeOH): 204.0, 226.0, 248.0, 330.0 nm. IR(KBr) υmax:3454, 3032, 2638,1630, 1589,1514, 1430, 1281 cm"1. GC/MS m/z 361(M++1, 7.00) , 360(M+, 5.00), 359(M+-1,6.00), 358(M+-2, 5.00), 301(13.0), 281(21.0), 280(100.00), 207(25.00). Anal (Cι6Hι4BrN3O2.HCl) C, H, N.
4— (2 ',6'—Dibromophenyl)-amino-6, 7— dimethoxyquinazoline (HI-P262) :
Yield 69.45%, mp 243.0-246.0 °C, JH NMR( DMSO-d6) : δ 11.91(d, IH, -NH), 8.80(s, IH , 2-H), 8.43(s, IH, 5-H), 7.86(d, 2H, J= 8.4 Hz, 3', 5'-H), 7.49(s, IH, 8H), 7.35(t, IH, J= 8.4 Hz, 4'-H), 4.02(s,3H, -OCH3), 4.01(s,3H, -OCH3 ). UV(MeOH): 208.0, 227.0, 245.0, 330.0 nm. IR(KBr)υmax:3454, 3032, 2638,1630, 1589,1514, 1430, 1281 cm"1. 4-(2',4'-Dibromophenyl)-amino-6, 7-dimethoxyquinazoline (HI-P263):
Yield 70.62 %; m.p.257.0- 262.0 °C. Η NMR(DMSO-d6) : δ 11.91(d, IH, -NH), 8.79 (s, IH, 2-H), 8.21(s, IH, 5-H ), 8.12-7.51(m. 3H, 3',5',6'-H), 7.35(s, IH, 8- H), 4.01(s,3H, -OCH3 ), 3.99(s, 3H, -OCH3 ). UV(MeOH):208.0, 210.0, 248.0, 330.0 nm. IR(KBr) υmax: 3458, 3028, 2641, 1633, 1594, 1511, 1435, 1277 cm"1.
Example 3 Chlorine Substituted Quinazoline Compounds Chlorine substituted quinazoline derivatives were synthesized and characterized as discussed above in Example 1. The structures and physical data are shown below:
Figure imgf000022_0001
4— (3 '—Chlorophenyl)-amino—6, 7-dimethoxyquinazoline(HI-P87) Yield 76.98%; m.p. 242.0-245.0°C. 1H NMR(DMSO-d6 : δ 10.47(br, s, IH, NH), 8.69(s, IH, 2-H), 8.06(s, IH, 5-H), 7.95-7.23(m, 4H,2', 4', 5'. 6'-H), 7.24(s, IH, 8-H), 3.98(s, eH, -OCH3), 3.35(s,3H, 0OCH3). UV(MeOH): 228.0, 251.0, 332.0 nm. IR(KBr)υmax: 3406, 2839, 1632, 1516, 1443. 1278, 1068 cm"1. GC/MS m/z 316(M+-1, 68.34), 314(M+-2, 100.00, 344(11.34), 222(4.35), 140(9.86). Found: C, 54.62; H, 4.68; N, 11.93; CI, 19.23. Cι6Hι4CIN3O2.HCl requires: C, 54.70; H, 4.28; N, 11.96; CI, 19.96%. 4-(c '-Chloroo-6 '-hydroxyphenyl)amino-6, 7-dimethoxyquinazoline(HI-P93)
Yield 83.08%; m.p.295.0°C.(dec). 1H NMR9DMSO-d6: δ 10.14(s, IH, -OH), 8.37(s, IH, 2-H), 7.78(s, IH, 5H), 7.57(d, IH, J2.4.=2.4 Hz, 2'-H), ), 7.16(s, IH, 8- H), 7.07(dd, IH, J2.4.=2.4 Hz, J4.5.=8.7 Hz, 4'-H), 6.92(d, IH, Λr, 5-=8.7 Hz, 5'-
H),3.93(s,3H, -OCH3). 3.92(s,3H, -OCH3). UV(MeOH): 205, 229.0, 251.0, 320.0 nm. IR(KBr)υmax: 3500(br), 3430, 2835, 1622, 1512, 1432, 1259 cm"1. GC/MS m/z 333(M+ +2, 13.41), 332(M+ +1, 9.73, 331(M+, 39.47), 314(M+ - OH, 100.00), 298(7.64). Found: C, 52.25; H, 4.07; N, 11.39. C,6H14CIN3O3.HCl requires: C, 52.32; H, 4.09; N, 11.44%.
4— (4 '—Hydroxyl— 3 ',5'—dichlorophenyl)amino-6, 7—dimethoxyquinazoline(HI— P189) Yield 79.45%; m.p. 293.0-295.0°C. 'HNMR-DMSO-d6): δ 1 1.32(s, IH, - NH), 10.34(s, IH, -OH), 8.87(s, IH, 2-H), 8.29(s, IH, 5-H), 7.90(s, 2H, 2', 6'-H), 7.32(s, IH, 8-H), 4.01(s, 3H, -OCH3), 3.99(s, 3H, -OCH3). UV(MeOH): 213.0, 232.0, 250.0, 335.0 nm. IR(KBr)υmax: 3479, 2564, 1641, 1579, 1429, 1282. 1147 cm"1. GC/MS m/z 367(M+ = 2, 66.57), 366(M+ = 1, 75.91), 365(M+, 100.00), 364(M+-1, 94.08), 349(M+- OH, 11.16). Anal. (Cι6Hι3Cl2N3O3) C, H, N. Found: C48.93; H, 4.51 ; N, 10.00. Cι7oHI7Cl2N3O3.Hcl requires: C, 48.80; H, 4.31 ; N, 10.04. %.
4— (3 '—Chloro- '- hydroxylphenyl)- amino- 6, 7— dimethoxyquinazoline (HI— P197). Yield 84.14%; m.p. 245.0°C(dec). 1H NMR(DMSO-d6): δ 10.00(s, IH - NH), 9.37(s, 1H -OH), 8.41(s, IH, 2-H), 7.78(s, IH, 5-H), 7.49(d, IH, J2. =2.7 Hz, 2'-H), 7.55(dd, 1H, J5.6.=9.0 Hz, Jr ff=2.7 Hz„ 6'-H), 7.16(s, IH, 8-H), 6.97(d, IH, J5.,6'=9.0 Hz, 5'-H), 3.93(s, 3H, -OCH3), 3.91(s, 3H, -OCH3). UV(MeOH): 209.0, 224.0,249.0, 330.0 nm. IR(KBr)υmax: 3448, 2842, 1623, 1506, 1423, 1241 cm"1. GC/MX m z: 341 (M+, 100.00), 326(M+-CH3, 98.50), 310(M+-OCH3, 12.5), 295(9.0.), 189(13.5), 155(13.8). Found: C.521.35; H, 4.16; CI, 19.15; N, 11.39. Cι6H14ClN3O3. HCl requires: Q52.32; H, 4.09; CI, 19.07; N, 11.44%.
4- (2 '-Chlorophenyl)-amino-6, 7-dimethoxyquinazoline (HI-P268) Yield 87.28%; m.p. 247.0-279.5°C. Η NMR(DMSO-d6): δ 11.71 (s, IH, - NH), 8.78 (s, IH, 2-H), 8.33 (s, IH, 5-H), 7.67 (s, IH, 8H), 7.68-7.42 (m, 4H, 3',4,5,6'-H), 4.00 (s, 3H -OCH3), 3.99(s, 3H, -OCH3). UV(MeOH): 213.0, 234.0, 251.0, 331.0 mn. IR(KBr)υmax: 3479, 2566, 1643, 1577, 1429, 1282, 1147 cm"1. GC/MX m/z 317 (M++1, 6.60), 316(M+, 6.60), 315(M+-1, 18.52), 314(M+-2, 11.11), 281 (21.22), 280 (M+-C1, 100.00), 264 (29.62). Found: C, 54.51; H, 4.41; N, 11.81. C16H,4ClN3O2. HCl requires: C, 54.45; H, 4.26; N, 11.93%.
4-(4'-Chlorophenyl)-amino-6, 7-dimethoxyquinazoline (HI-P269) Yield 94.94%. m.p. 248.0-250.0°C. 1H NMR(DMSO-d6): δ 11.62 (s, IH, -NH), 8.85 (s, IH, 2-H), 8.42 (s, IH, 5-H), 7.88 (d, 2H, J=8.7 Hz, 3',5',-H), 7.54 (d, 2H, J=8.7 Hz, 2',6',-H), 7.38 (s, IH, 8-H0, 4.02 (s, 3H, -OCH3), 3.99(s, 3H, -OCH3). UV(MeOH): 215.0, 230.0, 253.0, mn. IR(KBr - 3477, 2563, 1640, 1578 cm"1. GC/MX m/z 317 (M++l, 18.18), 316(M+,29.55), 315 (M+-l,48.85), 314 (M+-2, 61.36), 281 (32.,95), 207 (100.00). Found: C, 54.65; H, 4.38; N, 11.92. C16Hι4ClN3O2. HCl requires: C, 54.55; H, 4.26; N, 11.93%. 4-(4'-Hydroxyl-2 '-chlorophenyl)-amino-6, 7 -dimethoxy- quinazoline (HI-
P278) Yield 81.44%; m.p. 245.0-247.0°C. 1H NMR(DMSO-d6): δ 11.39(s, IH, - NH), 10.30(s, IH, -OH), 8.75(s, IH, 2-H), 8.24(s, IH, 5-H), 7.38-6.85(m, 3H, 3',5',6'-H), 7.37(s, IH, 8H), 3.98(s,3H, -OCH3), 3.96(s,3H, -OCH3). UV(MeOH): 222.0, 234.0, 239.0, 245.0, 254.0, 348.0 nm. IR(KBr)i- 3448, 3242, 3144, 3025, 2917, 2834, 1638, 1591, 1514, 1437, 1365, 1277, 1209 cm"1. GC/MS m z: 332(M++1, 5.00), 331(M+, 17.00), 330(M+-1, 5.00), 297(17.00), 296(100.00), 281(18.00), 280(29.00), 253(9.00). Found: C.52.17; H,4.06; N,1 1.32. C16H14ClN3O3. HCl requires: C.52.32; H,4.01; N, 1 1.44%.
4- (4 '-Chloronaphthy-1 ')-amino-6, 7-dimethoxyquinazoline (HI-P415) Yield, 85.07%. m.p. 245.0-248.0°C 'H NMR(DMSO-d6): δ 11.91(s, IH, -NH), 8.66(s, IH, 2-H), 8.45(s, IH, 5-H), 8.30-7.62(m, 6H, 2', 3', 5', 6', 7', 8'-H), 7.38(s, IH, 8- H), 4.03(s, 3H, -OCH3), 4.01(s, 3H, -OCH3). UV(MeOH): 211.0, 233.0, 250.0, mn. IR(KBr)υmax: 3481, 2567, 1645, 1579cm"1. Found: C, 59.32; H, 4.27; N, 10.24. C20Hi6ClN3O2. HCl. requires: C, 59.70; H, 4.23; N, 10.48%.
Example 4 Iodine Substituted Quinazoline Compounds
Iodine substituted quinazoline derivatives were synthesized as discussed above in Example 1, and analyzed. The structures and physical data are shown below: Iodine Substituted Quinazoline Compounds
Figure imgf000024_0001
Figure imgf000025_0001
4-(2 '-Iodophenyl)-amino-6, 7-dimethoxyquinazoline (P-270) :
Yield 75.37%; m.p. 225.0-230.0 °C. 1H NMR( DMSO-d6) : δ 11.74(s, IH, -NH), 8.79(s, IH , 2-H), 8.33(s, IH, 5-H), 8.05-7.13(m, 4H, 3',4,5,6'-H), 7.44(s, IH, 8H), 4.01(s, 6H, -OCH3 ). UV(MeOH): 219.0, 222.0, 253.0, 342.0 nm.. IR(KBr)υmax:3165, 3027, 2827, 1639, 1572, 1501, 1434, 1275, 1070 cm"1. GC/MS m/z 408(M++1, 3.47) , 407(M+, 15.28), 406(M+-1,3.47), 281 (33.33), 280(M+-I, 100.00), 264(50.00), 207(34.72 ). Found: C, 43.62; H, 3.60; N, 9.42. Cι6Hι4IN3O2.HCl requires: C, 43.34; H, 3.38; N, 9.48%.
4— (3 '-Iodophenyl)-amino-6, 7-dimethoxyquinazoline (HI-P271):
Yield 79.85%; m.p. 235.0-242.0 °C. 1H NMR( DMSO-d6) : δ 11.43 ( s, IH, -NH), 8.88 ( s, IH, 2-H ), 8.33 ( s, IH, 5-H ), 8.13(s, IH, 2'-H ), 7.80-7.26 ( m, 3H, 4',5',6'-H ), 7.35 ( s, IH, 8H ), 4.02 ( s, 3H, -OCH3 ), 4.00 ( s, 3H, -OCH3 ). UV(MeOH):.203.0, 210.0, 228.0, 251.0, 331.0 nm. (KBr) υmax: 3191, 3022, 2940, 2836, 2576, 1629, 1516, 1444, 1276,1153, 1060 cm1. GC/MS m/z 406( M+, 1.52 ), 405( M+-l, 6.22) , 281 (35.33), 207 (100.00). Found: C, 43.55; H, 3.43; N, 9.32. C16H14IN3O2.HCl requires: C, 43.34; H, 3.38; N, 9.48%. 4-(4'-Hydroxy-3,5-diiodophenyl)-amino-6, 7 -dimethoxy- quinazoline (HI- P294:
Yield 77.47%; m.p. 259.0-260.0 °C. Η NMR(DMSO-d6): δ 11.13(s, IH, NH), 9.73(s, IH, -OH), 8.87(s, IH , 2-H), 8.16(s, IH, 5-H), 8.09(s, 2H, 2' ,6'-H) , 7.28(s, IH, 8H), 3.98(s, 6H, -OCH3). UV(MeOH)λmax (ε ):. 217.0 , 227.0, 252.0 nm. IR(KBr)υmax: 3457,3201, 2934, 2832, 2566, 1629, 1562, 1521, 1439, 1275, 1075 cm '. GC/MS m/z: GC/MS m/z 422(M+-I,33.53), 405(7.50), 281(86.67) 221 (51.80), 207(91.30). Found: C, 32.60; H, 2.50; N, 6.92. Ci6H13I2N3O3.HCl requires: C, 32.82; H, 2.39; N, 7.18%. -(4 '-Hydroxy-3 '-iodophenyl)-amino-6, 7-dimethoxyquinazoline(HI-P299)
Yield 71.59 %; m.p. 248.0-250.0 °C. 1H NMR(DMSO-d6): δ 11.32(d, IH NH) 10.62(s, IH, -OH, 8.79(s, IH , 2-H), 8.26(s, IH, 5-H), 7.98 - 6.98(m, 3H, 2\3',6'- H), 7.32(s, IH, 8H), 3.98(s, 3H, -OCH3), 3.97(s, 3H, -OCH3). UV(MeOH)λmax (ε ): 217.0 , 227.0, 252.0 nm. IR(KBr)υmax: 3411, 2975, 2730, 2366, 1634, 1573, 1501, 1429, 1229, 1075 cm"1. GC/MS m z: 406(M+-1,3.33), 405(M+-2, 7.50), 281 (M+- 1-1, 26.67 ), 253(11.80), 207(100.00). Found: C, 41.96; H, 3.40; N, 8.98. Cι6H14IN3O3.HCl requires: C, 41.83; H, 3.26; N, 9.15%.
4-(4'-Iodophenyl)-amino-6,7-dimethoxyquinazoline (HI-P300): Yield 85.24%; m.p. 240.0-242.0 °C. 1H NMR( DMSO-d6) : δ 1 1.51 ( s, IH, NH), 8.82 ( s, IH , 2-H ), 8.37 ( s, IH, 5-H), 7.81 ( d, 2H, J- 8.4 Hz, 2', 6'- H ), 7.55 ( d, 2H, J= 8.4 Hz, 3', 5'- H ), 7.35 ( s, IH, 8H ), 4.01 ( s, 3H, -OCH3 ), 3.98( s, 3H, -OCH3 ). UV ( MeOH):. 217.0 , 227.0, 252.0 nm. IR ( KBr ) υmax: 3211, 3032, 2832, 2720, 1629, 1573, 1501, 1434, 1235,1153, 1070 cm"1. GC/MS m z 406(M+- 1,3.33), 405(M+-2, 7.50), 281 (M -I, 26.67 ), 253(11.80), 207(100.00). Found: C, 43.40; H, 3.39; N, 9.36. Cι6H14IN3O2.HCl. requires: C, 43.34; H, 3.38; N, 9.48%.
Example 5
OH Group Substituted Quinazoline Compounds
OH group substituted quinazoline derivatives were synthesized and characterized as discussed above for Example 1. The structures and physical data are shown below:
Figure imgf000026_0001
Figure imgf000027_0001
Figure imgf000028_0001
Figure imgf000029_0001
Figure imgf000030_0001
4— (3 '-Chlooro-6'-hydroxylphenyl)amino-6, 7-dimethoxyquinazoline(HI-P93) yield 93.08%; m.p.295.0°C.(dec). "H NMR-DMSO-d6: δ 10.14(s, 1H, -NH), 9.16(s, IH, -OH), 8.37(s, IH, 2-h), 7.78(s, IH, 5H), 7.57(d. lH, J2.2'= 2.4Hz, 2' - H), ), 7.16(s, IH, 8-H), 7.07(dd. IH, J2.4.=2.4 Hz, J4. y=8.7 Hz, 4' -H), 6.92(d, IH, J4.,5- - 8.7 Hz, 5'-H), 3.93(s,3H, -OCH3). 3.92(s,3H, -OCH3. UV(MeOH): 205, 229.0, 251.0, 320.0 nm. IR(KBr)υmax: 3500(br), 3430, 2835, 1622, 1512, 1432, 1259 cm"1. GC/MS m z 333(M" =2, 13.41), 332(M" =1, 9.73), 331(M+,39.47), 314(M+ -OH,100.00). 298(7.64). Found: C, 52.25; H, 4.07; N, 11.39, C16H14CIN3O3,HCI requires: C, 52.32; H, 4.09; N, 11.44%.
4-(3',5'-Dibromo-4'-hydroxylphenyl)-amino-6,7-dimethoxyquinazoline-(HI- P97). Yield 72.80%; m.p.> 300.0°C. Η NMR(DMSO-d6): δ 9.71(s, IH, -NH), 9.39(s, IH, -OH), 8.48(s, IH, 2-h), 8.07(s, 2H, 2', 6'-H), 7.76(s, IH, 5-H), 7.17(s, IH, 8-H), 3.94(s, 3H, -OCH3, 3.91(s, 3H, -OCH3). UV(MeOH): 208.0, 210.0,
245.0, 320.0 nm; IR(KBr)υmax: 3504(br), 3419, 2868, 1627, 1512, 1425, 1250, 1 155 cm"1; GC/MS m/z 456(M'=1, 54.40), 455(M", 100.00), 454(M~1, 78.01), 439(M~- OH, 7.96), 376(M"+1-Br, 9.76), 375(M""Br, 10.91), 360(5.23). Anal. (C16H13Br2N3O3) C, H, N.
4— (4 '-Hydroxylphenyl) — amino-6, 7-dimethoxyquinazoline(HI-P131) : yield 84.29%; m.p. 245.0- 248.0 °C. IR(KBr)υmax: 3428, 2836, 1635, 1516, 1443, 1234 cm: 1H NMR(DMSO-d6: δ 11.21(s, IH, -NH), 9.70(s, IH, -OH), 8.74(s, IH, 2- h), 8.22(s, IH, 5-h), 7.40(d, 2H, J- 8.9 Hz, 2',6'-H), 7.29(s, IH, 8-H), 6.85(d, 2H, J= 8.9 Hz, 3', 5'-H), 3.98(s, 3H, -OCH3, 3.97(s, 3H, -OCH2). GC/MS m/z 298
(M"=l, 100.00), 297(M", 26.6), 296(M+-1, 12.5). Anal. (Cι6HI5N3O3HCl) CI, H, N.
4— (2 '-Hydroxylphenyl)-amino-6, 7-dimethoxyquinazoline(HI-P132) : yield 82.49%; m.p. 255.0-258.0 °C. IR(KBr)υmax: 3500 (br), 3425, 2833, 1625, 1512, 1456, 1251, 1068 cm"1. 1H NMR(DMSO-d6): δ 9.78(s, IH, -NH), 9.29(s, IH, - OH), 8.33(s, IH, 2-h), 7.85(s, IH, 5-H), 7.41-6.83(m, 4H, 3',4', 5', 6'-H), 7.16(s, IH, 8-H), 3.93(s, 3H, -OCH3, 3.92(s, 3H, -OCH3), 280(M+-OH, 10.0). Anal. (C16H15N3O3, HCl) C, H, N. 4— 1(8 '-Hydroxyquiline)-5 '-Jamino-6, 7—dimethoxyquinazoline(HI-P133) yield 83.51%; m.p. 238.0-239.0°C. iH NME(DMSO-d6: δ 10.12(br,s, IH, -NH), 8.93- 7.09 M, 8H, 2, 5, 2, 2', 3', 4', 6', 7'-H), 4.04(s,3H, -OCH3), 3.96(s,3H, -OCH3). UV(MeOH): 204.0, 245.0, 332.0 nm. IR(KBr)υmax: 3425(br), 2935, 1632, 1510, 1437, 1273 cm"1. GC/MS m z 349(M" = 1,100.00), 348(m+, 26.56), 307(38.50), 289 (21.00).
4-[(3 '-Hydroxylpyridine)-2 'J-amino-6, 7-dimethoxyquinazoline(HI-P150)
Yield 78.65%; m.p. 185.0-187.0 °C. 'H NMR(DMSO-d6): δ 10.08(br,s, IH, - NH), 8.52(s, IH, 2-H), 7.88-7.86(m, IH, 6'-H), 7.60(s, IH, 5-H), 7.39-7.35(m, IH, 4'-H), 7.32(s, IH, 8-H), 6.63-6.58(m, IH, 5'-H), 5.96(s, IH, -OH), 3.97(s,3H, -OCH3), 3.94(s, 3H, -OCH3). UV(MeOH): 204.0, 238.0, 321.0 nm. IR(KBr)υmax: 3500, 3446, 2960, 1475, 1236, 1375, 1182 cm"1. GC/MS m/z 299(M" =1, 100), 298(M+, 34), 289(11), 291(9). Found: C, 60.26; H, 4.81 ; N, 18.68. C15Hι4N4O5, requires: C, 60.26; H, 4.81; N, 18.68%.
4- (3 '-Bromo-4 '-hydroxylphenyl)-amino-6, 7-dimethoxyquinazoline(HI- P154); yield 89.90%; m.p.233.0-233.5 °C. 1H NMR(DMSO-d6): 10.08(s, lh, - NH), 9.38(s, IH, -OH), 8.40(s, IH 2-H), 7.89(d, IH, J2># = 2.7 Hz, 2'-H), 7.75(s, IH, 5-h), 7.55(dd, IH, Jy & = 9.0 Hz, J2.6. = 2.7 Hz, 6'-H), 7.14(s, IH, 8-H), 6.97(d, IH, J,, 6. = 9.0 Hz, 5'-H), 3.92(s, 3H, -OCH3), 3.90(s, 3H, -OCH3). UV(MeOH): 203.0, 222.0, 25.0, 335.0 nm. IR(KBr)υmax_ 343 l(br), 2841, 1624, 1498, 1423, 1244 cm"1. GC/MS m/z 378(M+ -2, 90.68)", 377(M+ =1, 37.49), 376(M+, 100.00), 360(MK+, 3.63), 298(28.86), 282 (6.65). Anal. (C16Hι4BrN3O3,HCl) C, H, N.
4-(3 '-Hydroxyphenyl)-amino-6, 7-dimethoxyquinazoline(HI-P180) Yield 71.55%; m.p. 256.0-258.0 °C. IR(KBr)υmax: 3394, 2836, 1626, 1508, 1429, 1251 cm"1. 1H NMR(DMSO-d6): 9.41(s, IH, -NH), 9.36(s, IH, -OH), 8.46(s, IH, 2- H), 7.84(s, IH, 5-H), 7.84-6.50(m, 4H, 2', 4', 5', 6' -H), 7.20(s, IH, 8-H), 3.96(s, 3H, -OCH3), 3.93(s, 3H -OCH3). GC/MS m/z: (C16H15N3O3.HCl) C, H, N.
4— (4 '-Hydroxyl-3 '-Carboxyphenyl)—amino-6, 7-dimethoxyquinazoline (HI- P182) Yield 79.25%; m.p. > 300.0 °C. "H NMR(DMSO-d6)I: δ 10.53(s, IH, - NH), 8.53(s, IH, 2-H), 8.10-78.2(m, o3H, 2*, 5', 6', - H), 7.26(s, IH, 5-H), 6.9(s, IH, 80H), 4.01(s,3H, -OCH3), 3.99(s, 3H, -OCH3). UV(MeOH): 210.0, 239.0, 335.0 nm. IR(KBr)υmax 3421, 2839, 1686, 1631, 1508, 1491, 1280 cm"1. GC/MS m z 341(M+, 7.91), 323(M+ - OH, 12.19), 297(M+ - COOH, 12.35), 296(M+ - COOH -1.1760), 295(M+ - COOH - 2, 28.65), 206 (11.28).
4-(4 '-Hydroxyl-3 ',5'-dicholophenyl-6, 7-dimethoxyquinazoline(HI-P189) Yield 79.45%; m.p. 293.0-295.0 °C. Η NMR(DMSO-d6): 11.32(s, IH, -NH), 10.34(a, IH, -OH), 8.87(s, IH, 2-H), 8.29(s, IH, 5-H), 7.90(s, 2H, 2', 6'-H), 7.32(s, IH, 8-H), 4.01(s, 3H, -OCH3), 3.99(s, 3H, -OCH3). UV(MeOH): 213.0, 232.0, 250.0, 335.0 nm. IR(KBr)υmax: 3479, 2564, 1641, 1579, 1429, 1282, 1 147 cm"1. GC/MS m z 367(M+ + 2, 66.57), 366(M+ + 1, 75.91), 365(M+, 100.00), 364(MM, 94.08), 349(M OH, 11.16. Anal. (C16Hι3Cl2N3O3) C, H, N. Found: C, 48.93; H, 4.51 ; N, 10.00. -H1-Cl2N3O3. HCl requires: C, 48.80; H, 4.31 ; N, 10.04%.
4— (4 '-Bromo-6'-hydroxymethylphenyl)-amino-6, 7-dimethoxyquinazoline(HI- P190) Yield 7o3.08%; m.p. 222.0-223.0 °C. 1H NMR(DMSO-d6): δ 1 1.30(s, IH, -OH), 8.22(s, IH, -NH)O, 7.77.7.23(m, 5H, 5, 8, 2', 3', 5'-H), 4.49(s, 2H, PhCH2- H), 4.01(s, 3H, -OCH3), 3.90(s, 3H, -OCH3). UV(MeOH): 207.0, 250.0, 332.0 nm. IR(KBr)υmax: 3446, 2829, 2752, 1652, 1560, 1471, 1365, 1280 cm"1. GC/MS m z 391(M -1, 29.33), 389(M", 29.82), 360(M""CH2OH, 50.76), 358(52.39), 311(18.33). 280(43.20), 206(62.80), 191(100.00). Anal. (C17HloBrN3O3 HCl) C, H, N.
4-(6 '-Hydroxymethylphenyl)-amino-6, 7-dimethosyquinazoline(HI-P191)
Yield 78.45%; m.p. 215.0-218.0 °C. 1H NMR(DMSO-d6): δ 11.54(s, IH, -NH)O, 8.70(s, IH, 2-H), 8.34(s, IH, 5-H), 7.62-7.33(m, 4H, 3', 4', 5', 6'-H), 7.39(s, IH, 8-H), 4.49(s, 2H, PhCL OH), 3.99(s, 3H, -OCH3), 3.98(s, 3H, -OCH3). UV9MeOH): 209.0, 224.0, 246.0, 335.0 nm. IR(KBr)υmax: 3421, 2941, 1675, 2606, " 128, 1508, 1437o, 1244 cm"1. GC/MS m z 311(M", 38.07), 310(M" -1, 27.04), 28o0 (M~CH2OH, 100.00), 206(17.24), 191(51.34). 4-(2 ',4'-Dihydroxyphenyl)-amino-6, 7-dimethoxyquinazoline (HI-PI 92) Yield 86.25%; m.p. 240.0 °C(dec). 1H NMR(DMSO-d6): 10.92(s, IH, -NH), 976(s. IH, -OH), 9.59(s, IH, -OH), 8.67(s, IH, 20H), 81.9(s, IH, 8-H), 7.36(s, IH, 50H), 705(d, IH, J - 8.7 Hz, l'-H), 6.51(s, IH, 5'-H), 6.31(d, IH, J - 8.7 Hz, 3'-H), 3.98(s,6H, -OCH3). UV(MeOH): 206.0, 209.0, 223.0, 250.0, 342.0, 486 nm.
IR(KBR)υmax: 3391, 3139, 2938, 2850, 1633, 1607, 1567, 1509, 1447, 1359, 1220, 1189, 1055 cm"1. GC/MS m/z: 314 (M =1, 13.00), 313 (m", 72.80), 312(m+-l, 10.20), 296 (5.24), 206(17.50).
4— (2 ',3 '-Dihydroxyphenyl)-amino-6, 7-dimethoxyquinazoline (HI-P192) Yield 86.25%; m.p 240.0 °C(dec). Η NMR(DMSO-d6): 10.00(s, IH, -NH), 9.37(s, IH, -OH), 8.41(s, IH, 2-H), 7.78(s, IH, 5-H), 7.49(d, IH, J2<y = 2.7 Hz, 2'-H), 7.55(dd, lH, J5.6. = 9.0 Hz, J2.6. - 2.7 Hz, 6'-H), 7.16(s, IH, 8-H), 6.97(d, 1H, J5' 6' = 9.0 Hz, 5'-h), 3.93(s, 3H, -OCH3), 3.91(s, 3H, -OCH3). UV9MeOH): 209.0, 224.0, 249.0, 330.0 nm. IR(KBr)υmax: 3448, 2842, 1623, 1506, 1423, 1241 cm"1. GC/MS m/z: 341(M+, 100.00), 326(M~CH3, 98.50), 310(M+-OCH3, 12.5), 295(9.0), 189(13.5), 155(13.8). Found: C, 52.35; H, 4.16; CI, 19.15; N, 1 1.39. C16H14CIN3O3HCl requires: C, 52.32; H, 4.09; CI, 19.07; N, 1 1.44%.
4— (2 ',4 '-Dihydroxyl-1 ',3 '-diazineS ')-amino-6, 7-dime-thoxyquinazoline
(HI-P215) (Yield 89.23%, m.p. > 300.0 °C) 1H NMR(DMSO-d6): δ 8.59(s, IH, 2-H), 7.89(s, IH, 5-H), 7.60(d, IH, 6'-H), 7.09(s, IH, 8-H), 3.78(s, 3H, -OCH3), 3.76(s, 3H, -OCH3). UV(MeOH): 222.0, 246.0, 331.0 nm. IR(KBr)υmax: 3446, 3212, 3057, 1750, 1682, 1620, 1590, 1511, 1420, 1265 cm"1. GC/MS m/z: 315(M" .57.52), 206(46.50), 191(18.21), 127(100.00).
4-(3'—Hydroxymethylphenyl)-amino-6,7-dimethoxyquina-zoline(HI-P259) Yield 74.28%; m.p. 230.0-232.0 °C. Η NMR(DMSO-d6): δl 1.29(s, IH, -NH), 8.83(s, IH, 2-H)I, 8.28(s, IH, 5-H), 7.61-7.25(m, 4H, 2',4',5',6,-H), 7.36(s, IH, 8H)O, 4.57(s, 2H - CH2OH), 4.02(s, 3H, -OCH3), 4.00(s, 3H, -OC3). UV(MeOH): 207.0, 224.0, 251.0, 334.0 nm. IR(KBr)υmax: 3500, 3029, 1639, 1589, 1514, 1456, 1284 cm"1. GC/MS m/z: 281(M-+1- CH2OH, 54.00), 280(M~CH2OH, 100.00). Found: C, 58.68; H;, 5.30; N, 12.02. C16Hι5N3O2. HCl requires: C, 58.79; H, 5.19; N, 12.10%.
4-[4'-(2 "-Hydroxylethylphenyl)]-amino-6, 7-dimethoxyqui-nazoline (HI- P265) Yield 92.30%; m.p. 235.0-240.0 °C. Η NMR(DMSO-d6): δ 11.44(s, IH, -NH), 8.79(s, IH, 2-H), 8.34(s, IH, 5-h)I, 7.56(d, 2H, J=8.1 Hz, 2',6'-H), 7.34(d, 2H, J-8.1 Hz, 3',5'-H), 7.3 l(s, IH, 8H), 4.00(s, 3H, -OCH3), 3.99(s, 3H, -OCH3), 3.64(t, 2H, j-6.9 Hz, 1 "-H)I, 2.77(t, 2H, J=6.9 Hz, 2"-H). UV(MeOH): 204.0, 226.0, 251.0, 335.0 m. IR(KBr)υmax: 3361, 3015, 27o6o7, 1628, 1581, 1514, 1432, 1282 cm"1. GC/MS m/z: 281(17.00), 253(10.00), 207(100.00).
4-[2 '-(2 "-Hydroxylethylphenyl)]-amino-6, 7~dimethoxyqui-nazoline(HI P266)
Yield 87.69%; m.p/ 228.0-230.0 °C. 1H NMR-DMSO-d6): δ 11.32(s, IH, -NH), 8.74(s, IH, 2'-H), 8.13(s, IH, 5-H), 7.46-7.34(m, 4H, 3',4',5,6'-H), 7.32(s, IH, 8H), 4.00(s, 3H, -OCH3), 3.99(s, eH, -OCH3), 3.58(t, 2H, j- 7.2 Hz, 1 "-H), 2.75(t, 2H, J= 7.2 Hz, 2"-H). UV(MeOH): 210.0, 226.0, 249.0, 332.0 nm. IR(KBr)υ -"nmax- 3366, 3226, 3056, 2917o, 2685, 21638, 1571, 1514, 1467, 1277 cm"1. GC/MS m/z: 281(20.00), 253(9.00), 207(100.00).
4-(l '-Naphthol-4')-amino-6, 7-edimethoxyquinazoline(HI-P274) Yield 79.26; m.p. 205.0-208.0 °C. 1H NMR-DMSO-d6): δ 11.64(s, IH, -NH), 10.61(s, IH, - OH), 8.59(s, IH, 2-h), 8.41(s, IH, 5-H), 8.22-6.98(m, 5H, 3', 5', 6', 7',8'-H), 7.40(s, IH, 8H), 4.00(s, 3H, -OCH3), 3.99(s, 3H, -OCH3). UV9MeOH): 208.0, 215.0, 225.0, 240.0, 330.0 mn. IR(KBr)υmax: 3438, 321 1, 3061, 2932, 2834, 1633, 1576, 1509, 1437, 1380, 1276, 1215 cm"1. GC/MS m z: 281(51.00), 253(22.00), 207(88.00). Found: C, 62.26; H, 4.87; N, 10.77. C2oH17N3O3.HCl requires: C, 62.66; H, 4.70; N, 10.96%.
4- (2 '-Naphthol-1 f)-amino-6, 7-dimethoxyquinazoline(HI-P275) Yield 83.17%; m.p 218.0-220.0 °C. 1H NMR(DMSO-d6): δ 11.33(s, IH, -NH), 10.22(s, IH, -OH), 8.62(s, IH, 2-H), 8.40(s, IH, 5-H), 7.98-7.3 l(m, 6H, 3',4',5',6',7Υ-H), 7.41 (S, IH, 8H), 4.02(s, 3H, -OCH2), 4.00(s, 3H, -OCH3),. UV(MeOH): 206.0, 210, 219.0, 225.0, 230.0, 340.0 nm. IR(KBr)υmax: 3391, 3165, 3051, 2938, 2840, 1628, 1576, 1504, 1437, 1281, 1215 cm"1. GC/MS m/z: 348(M~ +1, 7.00), 347(M", 100.00), 346(M~1.22.00), 331(15.00), 330(12.00), 281(23.00), 253(12.00), 207(49.00). Found: C, 62.91 ; H, 4.76; N, 10.75. C20H1N3O3.HCI requires: C, 62.66; H, 4,70; N, 10.96%. 4-[3'-(l"-Hydroxyethyl)]-amino-6,7-dimethoxyquinazoline (HI-P276) Yield 79.21%; m.p. 215.0-218.0 °C. 1H NMR(DMSO-d6): δ 11.40(s, IH, -NH), 8.81(s, IH, 20H), 8.31(s, IH, 5-H)O, 7.60-7.26(m, 4H, 2',4',5',6,-H), 7.41(s, IH, 8H), 4.65(q, IH, J= 6.6Hz, -CH(OH)CH3), 4.00(s, 3H, -OCH3), 3.98(s, 3H, -OCH3), 1.350(d, 3H, J= 6.6 Hz, -CH3). UV9MeOH): 204.0, 216.0, 220.0, 224.0, 250.00, 348.0 nm. IR(KBr)υmax: 3407, 3030, 2977, 2840, 1643, 1591 1514, 1463, 1370, 1282, 1230 cm"1. GC/MS m z: 325(M"+1, 67.00), 324(M", 100.00), 323(M~ 1.22.00), 308(17.00), 307(56.00), 306(21.00), 281(2.00), 280(8.00), 264(6.00).
4- (4 '-Hydroxy-3 ',5 '-diphenylphenyl)-amino-6, 7-dime-hoxy quinazoline (HI-
P277) Yield 76.11%; m.p. 255.0-257.0 °C. Η NMR_DMSO-d6): δ 1 1.50(s, IH, -NH), 8.80(d, d, 2H, 2',6'-H), 8.58(s, IH, 5-H), 7.60-7.30(m, 10H, 3', 5', Ph-H), 7.39(s, IH, 8H), 4.00(s, 3H, -OCH3), 3.97(s, 3H, -OCH3), 1.350(d, eH, J= 6.6 Hz, - CH3). UV(MeOH): 210.0, 214.0, 229.0, 239.0, 345.0, 248.0, 352.0 nm. IR(KBr)υmax: 3520, 3218, 3023, 2935, 1630, 1562, 1518, 1457, 1281, 1234 cm"1. GC/MS m z: 281(35.00), 267(6.00), 253(10.00), 207(100.00). 4-(4'-Hydroxyl-2 '-chlorophenyl)-amino-6, 7-dimethoxy-quinazoline(HI-
P2878) Yield 81.44%; m.p. 245.0-247.0 °C. 1H NMR(DMSO-d6): δ l l.39(s, IH, -NH)O, 10.30(s, IH, -OH), 8.75(s, IH, 2-H), 8.24(s, IH, 5-H), 7.38-6.85(m, 3H, 3',5',6'-H), 7.37(s, IH, 8H), 3.98(s, 3H, -OCH3), 3.96(s, H3, -OCH3). UV(MeOH): 222.0, 234.0, 239.0, 245.0, 254.0 348.0 nm. (R(KBr)υmax: 3448, 3242, 3144, 3025, 2917, 2834, 1638, 1591, 1514, 1437, 1365, 1277, 1209 cm"1. GC/MS c/z: 332(M" +1, 5.00), 331(M", 17.00), 330(M"-1, 5.00), 297(17.00), 296(100.00), 281(18.00), 280o(29.00), 253(9.00). 4-(2 '-Hydroxy-naphthyl-3 ')-amino—6, 7-dimethoxyquinazolin(HI-P292)
Yield 87.41%; m.p. 277.0-279.0 °C. 1H NMR(DMSO-d6): δ 11.38(s, IH, -NH)O, 10.35(s, IH, -OH), 8.73(s, IH, 2-H), 8.25(s, IH, 5-H), 7.93-7.30(m, 6H, 1', 4', 5', 6', 7, 8'-H), 7.37(s, IH, 8H)O, 4.00(s, 6H, -OCH3). UV(MeOH): 204.0, 221.0, 224.0, 230.0, 256.0, 344.0 nm. IR(KBr)υmax: 3479, 3386, 3036, 2901, 1632, 1581, 1504, 1437, 1281 cm"1. GC/MS m/z: 281(41.00), 253(11.00), 207(100.00). Found: C, 62.87; H;, 4.83; N, lo0.78. C20HιN3O3. HCl requires: C, 62.66; H, 4.70, N, 10.96%.
4—(l '-Hydroxy-naphthyl-5 ')-amino-6, 70-dimethoxyquina-zoline(HI-P293)
Yield 87.21%; m.p. 204.0-205.0 °C. Η NMR(DMSO-d6): δ 1 1.73(s, IH, -NH), 10.43(s, IH, -OH), 8.65(s, IH, 2-H, 8.38(s, IH, 5-H), 8.21-6.95(m, 6H, 2', 3', 4', 6', 7, 8'-H), 7.33(s, IH, 8H)O, 4.00(s, 6H, -OCH3). UV9MeOH): 204.0, 214.0, 224.0, 229.0, 235.0 348 nm. IR(KBrυmax: 3449, 3335, 3102, 2927o, 1633, 1571, 1509, 1437, 1287 cm"1. Found: C, 62.23; H, 4.96; N, 10.89. C20Hι7N3O3.HCl requires. C, 62.66; H, 4.70; N, 10.96%.
4— (4 '-Hydroxy-3.5-diiodophenyl)-amino-6, 7-dimethoxy-quinazoline(HI- P294) Yield 77.47&; m.p. 259.0-260.0 °C. 1H NMR(DMSO-d6): δ l l.l3(s, IH, NH), 9.73(s, IH, -OH), 8.87(s, IH, 2-H), 8.16(s, IH, 5-H), 8.09(s, 2H, 1', 6'-H), 7.28(s, IH, 8H), 3.98(s, 6H, -OCH3),. UV(MeOH)λmax):. 217.0, 227.0, 252.00 nm. IR(KBrυmax: 3457, 3201, 2934, 2832, 2566, 1629, 1562, 1521, 1439, 1275, 1075 cm"1. GC/MS m z: GC/MS m/z 422(M~I.33.53), 405(7.50), 281(86.67), 221 (51.80), 207(91.30). Found: C, 32.60; H, 2.50; N, 6.92. C16Hι3I2N3O3.HCl requires: C. 32/82.' J. 2.39; N, 7.18%.
4— (4 '-Hydroxy-3 '-iodophenyl)-amino-6, 7-dimethoxyquinazoline(HI-P299)
Yield 71.59%; m.p. 248.0-250.0 °C. 1H NMR(DMSO-d6): δ 11.32(d, IH, NHO), 10.62(s, IH, -OH, 8.79(s, IH, 2-H), 8.26(s, IH, 5-H), 7.98 - 6.98(m, 3H, 2',3',6'- H), 7.32(s, IH, 8H), 3.98(s, 3H, -OCH3), 3.97(s, 3H, -OCH3). UV(MeOH) λmax (ε):. 217.0, 227.0, 252.0 nm. IR(KBr)υmax: 3411, 2975, 2730, 2366, 1634, 1573, 1501, 1429, 1229, 1075 cm"1. GC/MS m/z: 406(M 1.3.33), 405(M~2, 7.50), 281(MM-I, 26.67), 253(11.80), 207(100.00). Found: C, 41.96; H, 3.40; N, 8.98. Cι6H14IN3O3.HCl requires: C, 41.83; H, 3.26; N, 9.15%.
Table 5 Fluoroquinazoline Derivatives
Figure imgf000036_0001
(HI-P352) (H/-P353)
No R Formular MW
HI-P144 2-F, 3- -F, 5-F, 6-F, 4-Br C16H10BrF4N3O2 432
HI-P214 2-F, 4-Br Cι6H13BrFN3O2 378
HI-P218 3-CF3 C17H14F3N3O2 349
HI-P219 4-OCF3 C17H14F3N3O3 365
HI-P221 4-F C16H14FN3O2 299
HI-P223 4-CF3 C17H14F3N3O2 349
HI-P224 3-F C16H14FN3O2 299
HI-P228 2-CF3 CI7H14F3N3O2 349
HI-P232 4-SO2F Cι6HI4FN3O4S 363
HI-P264 2-F Cι6H14FN3O2 299
HI-P352 * C25H2oF N4O2 522
HI-P353 * C25H2oF6N O2 522
HI-P364 3-OCF3 Ci7Hι F3N3O3 365
HI-P365 2-OCF3 C17H14F3N3O3 365
HI-P366 3- -CF3, 5-CF3, Cι8Hj3F N3θ2 417
HI-P367 2- -CF3, 5-CF3, Cj8Hι3F6N3θ2 417
HI-P369 3-F, 4-OH C16H14FN3O3 315
HI-P408 3- •F, 5-F, 4-OH Cι6H13F2N3O3 333
Figure imgf000036_0002
HI-P352 HI-P353 Example 6
Fluorine Substituted Quinazoline Compounds
Fluorine substituted quinazoline derivatives were synthesized and characterized as discussed above for Example 1. The structures and physical data are shown below:
Figure imgf000037_0001
Figure imgf000038_0001
13 P-364 C17Hι4F3N3O3 365
14 P-365 Cι Hι4F3N3O3 365
15 P-366 C18H13F6N3O2 417
16 P-367 Ci8Hj3F N3O2 417
17 P-369 C16H14FN3O3 315
18 P-408 C16H13F2N3O3 33:
Figure imgf000039_0001
4— (2 ',3 ',5 ',6'-Terrafluoro-4'-bromophenyl)-amino-6, 7-dime- thoxyquinazoline (HI-P144) The yield 78.24%: m.p. 180.0-182.0 0°C. Η NMR (DMS O-d-): δ 7.78(s. IH. 2-H), 7.53(s. IH, 5-H), 6.79(s. IH, 8-H), 3.81(s.3H, - OCH3), 3.3.79(s.3 H, -OCH3). Found: C, 41.12; H, 2.41 : N, 9.89, C10H10 BrF- N3O2.HCI. requires: C, 41.11 ; H, 2.36; N, 9.93%.
4-(2 '-Fluoro— 4 '—bromophenyl)-amino-6, 7-dimethoxyquina-zoline (HI-P214)
The yield 77.21%; m.p. 247.0-252.0 0°C. Η NMR( DMSO-d6) : δ 8.57(s. IH. 2- H), 7.91(s. IH, 5-H), 7.57 (d. IH, 3'-H), 7.34(m. 2H. 5',6*-H). 7.07(s. IH, 8-H), 3.78(s. 3H. -OCH3), 3.77(s. 3H. -OCH3). UV(MeOH):.204.0, 215.0, 250.0, 330.0 nm.. IR(KBr) υmax: 3431, 2629, 1633, 1580, 151 1, 1420, 1278 cm"1. GC/MS m/z 379(MM,34.39), 378(M",31.33). 377(M"-1,39.08), 360(62.05), 359 (31.58), 358(62.57), 357(19.81), 299(19.31), 298(100.00), 282(17.88), 240(28.76).
4— (3 '-Trifluoromethylphenyl)-amino-6, 7-dimethoxyquinazo-line (HI-P218) The yield 85.61%: m.p. 242.0-245.0 0°C. 1H NMR(DMSO-d6) : δ 11.09(s. IH. - NH). 8.67(s. IH. 2-H), 8.03(s, IH, 5-H) , 7.92 -7.43(m, 4H, 2'4'5',6'-H). 7.10(s. IH. 8-H). 3.81(s, 3H, -OCH3), 3.79(s,3H, -OCH3). UV(MeOH):. 206.0. 276.0, 349.0 nm.. IR υmax (KBr) : 3372, 3257, 2935, 1626, 1512, 1380, 1225 cm"1.
GC/MS m/z 350(MM, 10.5) , 249(M".85.5). 173(M"-1, 100.0), 332( 10.5 ), 290 (8.8).
4-(4 '—Trifluoromethoxylphenyl)-amino-6, 7-dimethoxyqui-nazoline (HI-P219) The yield 83.14%; m.p. 228.0-230.0 0°C. 1H NMR(DMSO-d6) : δ 11.39(s, IH, - HN), 8.63(s, IH, 2-H), 8.18(s, IH, 5- H), 7.63(t, 2H, 3',5'-H) . 7.27(t, 2H, 2'. 6'-H). 7.15(s. IH, 8-H), 3.81(s, 3H, -OCH3), 3.78(s, 3H, - OCH3 ). UV(MeOH):. 209.0, 216.0 , 251.0 , 332.0 nm.. IR(KBr)υmax: 3207, 2839, 2762, 1633, 1508, 1480, 1276 cm"1. GC/MS m/z 366(MM, 12.50). 365(M~ , 75.00). 364(M"-1, 100.00), 348(17.50), 319(19), 306(8.00). 207(15.00).
4-(4'-Fluorophenyl)-amino-6, 7-dimethoxyquinazoline(HI-P221) The yield 84.25%:. 1H NMR(DMSO-d6) : δ 11.19(s. 1H, -HN ). 8.60(s. 1H, 2-H). 8.08(s. IH, 5- H)). 7.50(t, 2H, 3'-H) , 7.13(s. IH, 8-H), 7.12(t 2H, 2', 6'-H). 3.79(s. 3H. - OCH3 ), 3.78(s, 3H, -OCH3 ). UV (MeOH):. 225.0 , 251.0 , 333.0 nm.. IR
(KBr)υmax: 3205, 3007, 2837, 1633, 1580, 1508, 1470, 1220 cm"1. GC/MS m/z 300(MM, 10.76), 299(m", 76.92), 398(M"-1 , 100.00), 282(20.00).. 253(13.08), 207(3.80). Found: C, 57.17; H, 4.37; N, 12.47, Cι6H14FN3O2.HCl requires C. 57,31 : H, 4.48; N, 12.54%.
4- (4 '-Trifluoromethylphenyl)-amino-6, 7-dimethoxyquinazoline (HI-P223) The yield 91.70%: m.p. 243.0-245.0 0°C. Η NMR(DMSO-d6) : δ 11.47(s. IH. - NH), 8.67(s. IH, 2-H), 8.23(s. IH, 5-H), 7.79(d. 2H, J = 8.4 Hz. 3'5'-H). 7.61(d. 2H. J = 8.4 Hz. 2'6'-H ), 7.17(s. IH, 8-H) , 3.82(s. 3H. - OCH3), 3.78(s. 3H, - OCH3). GC/MS m/z 350(M +1, 11.00). 349(M", 65.00), 348(M"-1, 100.00), 332(18.50), 303(10.00), 207(18.50). Found: C, 53.01; H. 3.94; N, 10.88. C,- H14F3N3O2HCl requires C. 52.98; H. 3.90: N, 10.91%.
4-(4'-Flurophenyl)-amino-6, 7-dimethoxyquinazoline(HI-P224) The yield 88.69%; m.p. 254.0-255.0 0°C. 'H NMr(DMSO-d6): δ 11.16(s, IH, -HN), 8.67(s, IH, 2-H), 8.09(s, IH, 5-H), 7.13(s, IH, 8-H), 7.51-6/94(m, 4H, 2',3',5',6'-H)O, 3.80(s, 3H, -OCH3), 3.79(s, 3H, -OCH3). UV(MeOH): 206.0, 226.0, 251.0, 333.0, 343 nm.. IR(KBr)υmax: 3437, 3211, 2619, 1637, 1580, 1500, 1448, 1281 cm"1. GC/MS m/z (300(MM, 8.00), 299(M", 68.00), 398(M~1, 100.00), 282(21.60), 253(25.00), 207 (80.00),. Found: C, 57.25; H, 4.58; N, 12.42. Cι6H14FN3O2.Hcl requires C, 57.31; H, 4.48; N, 12.54%.
4-(2 '- Trifluoromethylphenyl)-amino-6, 7-dimethoxyquinazoline(HI-P228).
5 The yield 83.57%; m.p. 242.0-245.0 0°C. 1H NMR(DMSO-d6): δ 11.58(s, IH, - HN), o8.76(s, IH, 2-H), 8.25(s, IH, 5-H), 7.95-7.62(m, 4H, 3', 4', 5', 6'-H), 7.38(s, IH, 8-H), 4.01(s, 3H, -OCH3), 3.00(s, 3H, -OCH3). GC/MS m/z 350(M"+1, 8.50), 349(M",32.00), 348(M+-1.31.50), 328(18.50), 207(5.0)1, 280(M+-CF3, 100.00), 264(18.50), 207(32.50). Found: C, 52.71; H, 4.26; N, 10.91%. l o 4— [4 '- benzenes ulfanily I fluoride]- mino- -6, 7-dimethoxyquinazoline (HI-P232)
Yield 84.02%; m.p. 228.0-230.0 °C. 1H NMR9DMSO-d6): δ 11.62(s, IH, -HN), 8.78(s, IH, 2-H), 8.29(s, IH, 5-H), 8.12-8.02(m, 4H, 2",3",5",6"-H), 7.21(s, IH, 8-H), 3.86(s, 3H, -OCH3), 3.81(s, 3H, -OCH3). UV(MeOH): 208.0, 215.0, 253.0, 278.0, 338.0 nm.. IR(KBr)υmax: 3440, 3277, 2571, 1635, 1580, 1516, 1435, 1209 15 cm"1. GC/MS m/z: 281(43.00), 253(12.00), 207(100.00). Found: C, 48.13; H, 3.73; N, 10.53. C,6Hι4FN3O4S.HCl requires: C, 48.12; H, 3.76; N, 10.53%.
4-(2 '-Fluorophenyl)-amino-6, 7-dimethoxyquinazoline(HI-P264) Yield 73.58%; m.p. 233.0-235.0 0°C. 1H NMR(DMSO-d6): δ 11.69(d, IH, -NH), 0 8.82(s, IH, 2-H), 8.37(s, lH,k 50H), 7.59-7.32(m, 4H 3', 4' 5', 6'-H), 7.41(s, IH, 8H)O, 4.02(s, 3H, -OCH3), 4.01 (s, 3H, -OCH3). UV(MeOH): 204.0, 226.0, 248.0, 330.0 nm. IR(K_Brυmax: 3454, 3032, 2638, 1630, 1589, 1514, 1430, 1291 cm"1. GC/MS m/z 300(MM, 7.00), 299(M".38.00), 298(M"-1.22.00), 280(M_F, 100.00), 264(15.00), 207(35.00). Found: C, 57.12; H, 4.57; N, 12.45. 5 Cι6Hι4FN3O2.HCl requires: C, 57.31; H, 4.48; N, 12.54%.
4— {4 '-[2 "-(4 " '—Aminophenyl)-hexafluoropropyl]phenyl}-amino-6, 7- dimethoxyquinazoline(HI-P352) Yield, 80.41%, m.p. 280.0-282.0 °C. Η NMR(DMSO-d6): δ 11.87(s, IH, -NH), 8.91(s, IH, 2-H)I, 8.55-7.18(m, 10H, 5, 8, 0 2', 3', 5', 6', 2"', 3"', 5"', 6"'-H), 4.05(s, 3H, -OCH3), 4.00(s, 3H, -OCH3). 19F NMR(DMSO-d6): 128.76. Found: C, 50.33; H, 3.87; N, 9.57. C25H2oF6N4O2.2HCl requires: C, 50.50; H, 3.70; N, 9.42%
4-{3 '-[2"-(3'"-Aminophenyl)-hexafluoropropyl]phenyl}-amino-6, 7- dimethoxyquinazoline(HI-P353) Yield, 83.11%,. m.p. 292.0-284.0°C. Η 5 NMR(DMSO-d6): δ 11.68(s. IH. -NH). 8.81(s. IH. 2-H). 8.44-7.09(m. 10H. 5, 8, 2', 4', 5', 6*, 2'", 4'", 5'", 6"'-H). 4.00(s. 3H. -OCH,). 3.97(s. 3H. -OCH3). 19F NMR(DMSO-d6): 129.21. Found: C, 53.96: H,3.93; N,9.77. C25H2oF6N4O2.HCl requires: C. 53.76: H.3.76: N. 10.03%
4— (3 '-Trifluoromethoxylphenyl)-amino—6, 7-dimethoxyquinazoline (HI-P364) 0 Yield. 83.25%. m.p. 233.0-235.0°C. 1H NMR(DMSO-d6): δ 1 1.65(s, IH. -NH), 8.88(s. IH. 2-H), 8.41(s. IH, 5-H), 7.86-7.29(m, 4H, 2', 4', 5', 6' -H). 7.36(s. IH, 8-H), 4.02(s. 3H, -OCH3). 3.98(s. 3H, -OCH3). 19F NMR(DMSO-d6): 135.37. GC/MS m/z: 366(M++1, 11.0), 365(M+, 67.0), 364(M+-1, 100.0). Found: C, 50.93; H,3.75; N,10.61. C17H14F3N3O3.HCl requires: C, 50.97; H.3.74; N, 10.47%. 5 4- (2 '-Trifluoromethoxylphenyl)-amino-6, 7-dimethoxyquinazoline (HI-P365) Yield. 77.85%. m.p. 235.0-237.0°C. 'H NMR(DMSO-d6): δ 11.68(s. IH, -NH), 8.80(s. IH. 2-H). 8.32(s. IH, 5-H), 7.64-7.53(m, 4H, 3', 4', 5', 6' -H). 7.40(s. IH, 8-H), 3.99(s, 6H, -OCH3). 19F NMR(DMSO-d6): 135.71. GC/MS m/z: 366(M"+1, 2.0), 365(M+, 15.0), 364(M+-1, 4.0), 281(21.0), 280(M"-OCF3 100). Found: C, 50.83; H.3.79; N-10.52. Ci-H14F3N3O3.HCl requires: C, 50.87; H,3.74; N, 10.47%.
4-(3', 5'-Ditrifluoromethylphenyl)-amno-6, 7-dimethoxyquinazoline (HI- P366) Yield. 82.88% m.p. 270.0-272.0°C. 1H NMR(DMSO-d6): δ 1 1.87(s. IH, - NH), 8.97(s. IH, 2-H), 8.60)s. 2H, 2', 6'-H). 8.43(s. IH, 5-H), 7.98(s. IH, 4'-H), 7.35(s. IH, 8-H), 4.03(s. 3H, -OCH3). 3.99(s. 3H, -OCH3). f9F NMR (DMSO- d6): XX GC/MS m/z: 418(M"+1. 19.0), 417(M", 100.0), 416(M"-1, 73.0), 398(M" -F, 16.0), 398(M"-F, 16.0), 348(M"-CF3. 16.0). Found: C, 47.78; H.3.20; N.9.26. C,8H13F6N3O2.HCl requires: C. 47.68; H.3.09; N.9.27%.
4— (4 '-Hydroxyl-3 '-fluorophenyl)-amino-6, 7-dimethoxyquinazoline (HI-P369)
Yield. 84.28%. m.p. 268.0-270.0°C 1H NMR(DMSO-d6: δ 11.36(s. IH, -NH). 10.13(s, IH, -OH). 8.80(s. IH, 2-H), 8.30(s. IH, 5-H), 7.60-7.02(m. 3H. 2', 5', 6'- H). 7.3 l(s. IH, 8-H). 3.99(s. 3H, -OCH3), 3.97(s. 3H, -OCH3). 19F NMR(DMSO-d6): δ 57.38. Found: C, 54.90: H, 4.28; N.11.91. Cι6H14FN3O3.HCl requires C. 54.70; H, 4.27; N.l 1.97%.
4— (4 '-Hydroxyl-3 ',5 '-difluorophenyl)-amino-6, 7 -dimethoxy- quinazoline (HI- P408) Yield. 83.15%, m.p.228.0-230.0 0°C. ]H NMR(DMSO-d6): δ 1 1.46(s. IH,
-NH), 10.39(s. IH, 2-H), 8.36(s. IH, 5-H). 7.56, 7.54 (s. s. 2H. 2', 6'-H), 7.33(s.
IH. 8-H), 4.00)s. 3H, -OCH3), 3.98(s. 3H, -OCH3). 19F NMR(DMSO-d6: δ60.25,
60.22. Found: C, 52.04; H, 4.17; N,l 1.10. C16H13F2N3O3.HCl. requires C, 52.03;
H, 3.79; N,l 1.38%.
Example 7 Solubility profile of WHI-P131
The solubility of WHI-P131 free base was measured in water, propylene glycol, polyethylene glycols (PEGs), ethanol, and triglycerides. The results are summarized in Table 6. The solubility of WHI-P131 is very poor in water. It was about 35 times more soluble in C8-Cι0 medium chain triglyceride (Captex 300) than in water. It was much more soluble in ethanol and hydrophilic cosolvents such as propylene glycol and PEGs. WHI-P131 free base was most soluble in polyethylene glycols of greater than 10%, followed by propylene glycol (1.95%) and ethanol (1.86%). Parallel solubility measurements were also carried out using WHI-
P131 chloride salt. Table 1 shows that a 50 fold increase in water solubility was achieved when the free base form was converted into a chloride form. In contrast, the solubility of WHI-P131 chloride decreased drastically in all other liquids. As can be seen it Table 6, its solubility in Captex 300, ethanol, propylene glycol, PEG300, and PEG200 decreased by a factor of about 10 to 70 compared to the compound free base. These results show that the improvement of the solubility in water of the compound salt form was offset by a much larger decrease of its solubility in other liquids. This fact underscores the importance of knowing the solubility profile of both the free base and salt forms of an ionizable compound when making choices of its delivery vehicles.
Table 6: Solubility of WHI-P131 (mg/ml) free base versus
WHI— P131 chloride salt in various liquids
Figure imgf000043_0001
Example 8 Co-Solvent Vehicles
To further determine the effect of cosolvents on the solubility behavior of WHI-P131, the solubility of WHI-P131 chloride salt was carried out in binary mixtures of water-cosolvents. Solvents including ethanol, propylene glycol, and PEGs are used in several injectable formulations, and were considered here as possible vehicles for WHI-P131. Figure 1 shows that at PEG concentrations below 70%) in water, the solubility versus PEG concentration curves were practically superimposable for PEG300 and PEG200. However, at PEG concentrations greater than 70%), there was a large difference between the solubility behavior of WHI-P131 in water-PEG300 and water-PEG200 mixtures. For PEG300, the solubility continued to increase linearly with increasing PEG concentration, whereas for PEG200, a large increase in slopes occurred near 100%o PEG200. Since the solubility-PEG300 concentration curve is linear over the entire range of water- PEG300 mixtures, WHI-P131 solubilized in these mixtures at concentrations below its saturation point can be used as vehicles for this compound, since their dilution will not result in drug precipitation. In contrast, if one were to dilute by water a 2% WHI-P131 in PEG200, WHI-P131 concentration would fall above the solubility limit and precipitate out. Therefore, PEG300 is more appropriate for use as a cosolvent vehicle in the formulations of WHI-P 131.
Example 9 Micellar Solutions
Micellar solutions containing PEGylated phosphatidylethanolamines were exceptionally effective in enhancing the solubilization of WHI-P 131. Table 7 shows the compositions of several mixed micellar solutions containing various amounts of WHI-P131. Micellar solutions using purified soya lecithin (Phospholipon 90G) were feasible when an equal or higher amount of a nonionic surfactant (such as Cremophor EL for example) was also present. With PEGylated phospholipids, the presence of Cremophor EL was not necessary to form micellar solutions. In addition, an anionic PEGylated phosphatidylethanolamine seemed to be a better solubilizer for WHI-P131 than Phospholipon (mostly phosphotidylcholine). The enhanced solubilization observed with micellar solutions was apparently due to the charge interaction between the cationic WHI-P 131 and anionic PEGylated phosphatidylethanolamine. In Table 7, compositions MM3 and MM4 where PEG2000-DPPE and PEG5000-DPPE were present show the highest solubilization (highest drug to surfactant ratio). It was also found that the presence of Pluronic F-68 aided in preventing drug recrystallization.
To determine the solubilization enhancement by different types of surfactants in a more quantitative manner, solubility-surfactant concentration curves were plotted. Figure 2 depicts the amount of solubilized WHI-P131 chloride in a solution containing 20% of PEG300, and an increasing amount of PEG2000-DPPE. This figure indicates that, in the absence of surfactant, the solubility of WHI-P131 chloride salt in 20% PEG300 was 2.38 mg/ml. At low surfactant concentrations (below the CMC), the drug solubilization seems to remain unchanged, then increases linearily with surfactant concentration at higher PEG2000-DPPE concentration. The same solubilization characteristics were observed with other micellar solutions. In Table 8, the slopes of the linear portions of the plot for a series of nonionic surfactants and cosolvents were used to calculate the solubilization enhancement per unit surfactant or cosolvent concentration.
The solubilization enhancement, as represented by the amount of solubilized WHI-P131 (in milligram) per gram of surfactant, are shown in Table 8 to vary with the type of surfactants used. For the three PEGylated phosphatidylethanolamines, the solubilization enhancement depended on the hydrophobic chain length and polyoxyethylene number of the PEGylated phospholipids. PEG2000-DPPE and PEG5000-DPPE seemed to be the most effective solubilizers for WHI-P131 of the three PEGylated phosphatidylethanolamines investigated. Also shown in Table 8 for comparison purposes are the solubilization enhancements produced by the use of cosolvents. It can be seen that PEGylated surfactants were about 6 to 16 times more effective than cosolvents in producing solubilization enhancement of WHI-P131 chloride salt.
Table 7: WHI-P131 in mixed micelles
% Concentration
COMPONENT MM1 MM2 MM3 MM4
WHI-P131 0.18 0.26 0.43 0.37
Phospholipon 90G 0.0 1.28 0.0 0.0
PEG2000-DPPE (a) 0.0 0.0 1.84 0.0
PEG5000-DPPE (b) 1.16 0.0 0.0 2.51
Pluronic F-68 0.29 0.32 0.46 0.55
Cremophor EL 1.45 1.6 2.29 0.0
Propylene glycol 11.64 12.8 25.6 12.9
Water 85.3 83.7 69.4 83.7 Surfactants/Drug Ratio 16.1 12.1 10.7 8.3
(a) PEG2000 dipalmitoyl phosphatidylethanolamine
(b) PEG5000 dipalmitoyl phosphatidylethanolamine
Table 8: Solubilization enhancement of WHI-P131 in micellar solutions and cosolvent vehicles
Enhancer Vehicle type Solubilized WHI-P 131 (mg)
per gram of surfactant or solvent
PEG2000-PE Micellar solution 92.0
(16:0)
PEG2000-PE Micellar solution 76.6
(14:0)
PEG5000-PE Micellar solution 37.5
(18:0)
Pluronic F-68 Micellar solution 6.1
PEG400 Cosolvent 6.2
PEG300 Cosolvent 5.8
PEG200 Cosolvent 5.3
Example 10 Microemulsions
A series of ternary phase diagrams were constructed at room temperature, and several microemulsions within the single phase microemulsion region were examined for their capacity to solubilize WHI-P 131. A representative ternary phase diagram depicted in Figure 3, shows the location of the single phase microemulsion region. In this phase diagram, it can be seen that microemulsions containing up to 30% of Captex 300 were possible. These microemulsions were transparent and tolerated dilution very well when mixed with aqueous phases. In WHI-P 131 -containing microemulsions, the drug was first solubilized in the microemulsions chosen from the one phase region of the phase diagram with mild heating, followed by dilution with water or buffer solution at room temperature.
The microemulsion composition ME1 depicted in Table 9 was used in pharmacokinetic studies and biological activity assays. This microemulsion was prepared by first solubilizing WHI-P 131 in composition A in the ternary phase diagram, followed by a dilution with water (1 :9). Its volume-weighted average particle diameter as determined by dynamic light scattering was 24.8 nm prior to and 11.4 nm after the incorporation of WHI-P 131 chloride. Thus, the drug incorporation, in this case, resulted in the lowering of the particle size. The solubilization of WHI-P131 was at least 1.8 mg per ml of microemulsion. ME2 was a microemulsion composition obtained from a separate phase diagram not shown. This microemulsion can solubilize at least 2.8 mg of WHI-P131 per ml of microemulsion . Compared to the solubility of WHI-P 131 salt in the water of 1.2 mg/ml, ME2 had more than doubled the solubilization of WHI-P 131 in water. These microemulsions can readily be filtered through 0.2 μm filter, and stored at room temperature. The microemulsions and WHI-P 131 they contained were shown to be stable for an extended time at ambient temperature.
By converting WHI-P131 from its free base to its chloride salt form, a fifty fold increase in solubility was achieved raising the drug concentration from 0.025 mg/ml to 1.2 mg/ml. By adding 20% of PEG300 to the vehicle, the drug concentration further increased to 2.2 mg/ml. Furthermore, an incorporation of 3% of PEG2000-DPPE to the cosolvent vehicle brought the drug solubilization to 4.7mg/ml, which corresponds to a total solubilization enhancement of 190 fold. If a microemulsion formulation instead a cosolvent/micellar solution was used, a total solubilization enhancement of 110 fold. Lead micellar and microemulsion formulations of WHI-P 131 were as active as unformulated WHI-P 131 in DMSO. The miceller formulation inhibited allergic mast cell responses in vitro and prevented anaphy lactic shock in vivo.
These results demonstrates that microemulsions can be used to enhance the solubilization of WHI-P131. However, because of the low solubility of WHI-P131 in the oil, the drug incorporation into the microemulsion seemed to be limited to the surfactant interfacial film only which resulted in a relatively small solubilization enhancement. The lipid cores of the microemulsion droplets, in this case medium chain triglyceride, seemed to contribute very little to the solubilization enhancement. Table 9: Microemulsion compositions containing WHI-P131
Component %w/v
ME1 ME2
WHI-P131 chloride salt 0.18 0.28
Captex 300 2.2 1.2
Pluronic F-68 0.1 0.4
Cremophor EL 1.1 1.9
Phospholipon 90G 1.5 1.5
Propylene glycol 4.7 15.3
Purified water 90.2 79.4
Particle size 10 nm 15.9 nm
Example 11 Cumulative Solubilization Enhancement
The cumulative solubilization enhancement obtained using a combination of solubilization methods is illustrated in Figure 4. The overall enhancement appears to be additive. By converting WHI-P 131 from its free base to its chloride salt form, a fifty fold increase in solubility was achieved raising the drug concentration from 0.025 mg/ml to 1.2 mg/ml. By adding 20%o of PEG300 to the vehicle, the drug concentration further increased to 2.2 mg/ml. Furthermore, an incorporation of 3%> of PEG200-DPPE to the cosolvent vehicle brought the drug solubilization to 4.7mg/ml, which corresponds to a total solubilization enhancement of 190 fold. If a microemulsion formulation instead a cosolvent/micellar solution was used, one can reached a total solubilization enhancement of 110 fold.
Example 12 Micellar Formulation for Preclinical Studies in Mice Preparation of the propylene glycol/surfactant solution
The following materials were weighed into a glass vial: 1.124 g of PEG5000PE, 0.260 g of Pluronic F-68 and 5.704 g of propylene glycol. The mixture was stirred and heated at 70°C for 5 min or until all the solids were dissolved. The mixture turned into a clear colorless solution. It became solid upon cooling at the room temperature. The mixture was warmed to liquid before use.
WHI-P131 drug containing solution 68 mg of WHI-P131 CI" was dissolved in 4 ml of the above propylene glycol solution and 0.6 ml DI water. This drug mixture was heated at 70°C for 10 min until all the WHI-P131 was dissolved and the solution was yellow and clear. This drug solution was mixed into 27.95 ml of DI water dropwise. The diluted solution was yellow and clear. This drug solution was filtered through 0.2 μm filter under a laminar flow hood for sterilization. The filtrate was collected in a liquid scintillation vial. The WHI-P 131 concentration in the solution was 1.97 mg/ml. The composition of the solution was:
Figure imgf000049_0001
The control (vehicle solution
3.74 ml of the propylene glycol solution was mixed with 28.51 ml of DI water. The resulting solution was clear and colorless. This solution was filtered through a 0.2 μm filter under a laminar flow hood for sterilization. The filtrate was collected in a liquid scintillation vial. The composition of the solution was:
Figure imgf000050_0001
Example 13 Microemulsion Formulation for Preclinical Studies in Mice
Preparation of low hydrophylicity lipophylicity balance (HBL) phase (100 g):
The following materials were weighed into a 200 ml glass bottle: 2 g of Pluronic F-68, 18 g of Cremophor EL and 80 g of propylene glycol. The mixture was stirred and heated at 70°C until it turned into a homogeneous suspension.
Preparation of the high HLB phase OOP g):
40 g of Phospholipon 90G and 60 g of Captex 300 were weighted into a 200 ml size glass bottle. The mixture was stirred and heated at 70°C for several hours until it turned into a clear yellow solution.
Preparation of the Microemulsion (lOOg :
In a 200 ml glass bottle, the following components were added: 53.3 g of the high HLB phase, 33.3% of the HLB phase and 13.3 g of DI water. The bottle was hand shaken until the mixture became a transparent microemulsion.
Preparation of PI 31 Drug Microemulsion (96 ml of 0.20% WHI-P131 Solution:
220 mg of WHI-P131 was dissolved in 15.7 ml of the above microemulsion. The mixture was stirred and heated at 70°C for 30 min or until all solids were dissolved. WHI-P 131 concentration in this drug microemulsion was 14 mg/ml.
14 ml of this drug microemulsion was mixed into 84 ml DI water dropwise. WHI-P131 concentration in this solution was 2.0 mg/ml. The composition of the solution was shown in the following table:
Figure imgf000051_0001
Example 14. Pharmacokinetic study
Pharmacokinetic studies:
In pharmacokinetic studies, mice were injected intravenously via the tail vein with a bolus dose of 300 μg/mouse (-12.5 mg/kg = 34 μmoles/kg) of WHI- P131. Blood samples were obtained from the ocular venous plexus by retroorbital venupuncture prior to and at 3, 5, 10, 15, 30, 45 minutes, and 1, 2, 4, and 8 hours after administration of WHI-P 131. All collected blood samples were heparinized and centrifuged at 7,000 g for 10 min in a microcentrifuge to obtain plasma. The plasma samples were stored at -20°C until analysis. Aliquots of plasma were used for extraction and HPLC analysis. Pharmacokinetic modeling and parameter calculations were carried out using the software, WinNonlin Program, Version 2.0. An appropriate pharmacokinetic model was chosen on the basis of lowest weighted squared residuals, lowest Schwartz criterion, lowest Akaike's Information Criterion value, lowest standard errors of the fitted parameters, and dispersion of the residuals. The elimination half-life was estimated by linear regression analysis of the terminal phase of the plasma concentration profile. The area under the curve (AUC) was calculated by the trapezoidal rule between first (0 h) and last sampling time plus C/k, where C is the concentration of last sampling and k is the elimination rate constant. Systemic clearance (CLs) was determined by dividing the dose by the AUC. Statistical analysis was performed using the Instat program, 3.0. The significance of differences between pharmacokinetic parameters was analyzed using two-tailed t test, and P values < 0.05 were considered significant.
A highly sensitive quantitative HPLC detection method was used to determine the pharmacokinetics of WHI-P 131. In brief, the HPLC system consisted of a Hewlett Packard series 1100 equipped with an automated electronic degasser, a quaternary pump, an autosampler, an automatic thermostatic column compartment, diode array detector and a computer with a Chemstation software program for data analysis. A 250 x 4 mm Lichrospher 100, RP-18 (5 μm) analytical and a 4 x 4 mm Lichrospher 100, RP-18 guard columns were obtained from Hewlett Packard Inc. Acetonitrile/water containing 0.1 % of trifluoroacetic acid and 0.1%o triethylamine (28:72, v/v) was used as the mobile phase. The wavelength of detection was set at 340 nm. Peak width, response time and slit were set at >0.03 min, 0.5 s and 8 nm, respectively.
For determination of WHI-P131 levels, 10 μL of internal standard was added to a 100 μL plasma sample. For extraction, 7 ml chloroform was then added to the plasma sample, and the mixture was vortexed thoroughly for 3 min. Following centrifugation (300 g, 5 min), the aqueous layer was frozen using acetone/dry ice and the organic phase was transferred into a clean test tube. The chloroform extracts were dried under a slow steady stream of nitrogen. The residue was reconstituted in 100 μL of methanol: water (9: 1) and 50 μL aliquot of this solution was used for HPLC analysis. Under the described chromatographic separation conditions, the retention times for WHI-P131 and the internal standard were 5.1 minutes and 9.5 minutes, respectively. At the retention time, WHI-P131 and its internal standard were eluted without any interference peaks from the blank plasma. The plasma calibration standards were linear in 0.1 - 20 μM range. The coefficient of variation for within the day and from day-to-day was <10%>. The linear coefficient of determination was greater than 0.999. The lower limit of detection was 0.05 μM and the mean accuracy of quality control samples was between 90 - 110%) for all analysis days. Mast cell Inhibition Assay: RBL-2H3 mast cell line was obtained from Dr. Reuben P. Siraganian
(Laboratory of Microbiology and Immunology, National Institute of Dental Research, National Institute of Health). The cells were maintained as monolayer cultures in 75- or 150- cm flask in Eagle's essential medium supplemented with 20% fetal calf serum (Hamawy et. al., 1995, Cellular Signalling 7:535-544). RBL- 2H3 cells were sensitized with monoclonal anti-DNP IgE antibody (0.24 mg/ml) for lhour at 37 °C in a 48-well tissue culture plate. RBL-2H3 cells were allowed to adhere to the plate. Unbound IgE was removed by washing the cells with phosphate buffered saline. After washing, PIPES-buffered saline containing 1 mM calcium chloride was added to the monolayers of the RBL-2H3 cells. The cells were challenged with 20 ng/ml DNP-BSA for 30 minutes at 37°C. The plate was centrifuged at 200 g for 10 minutes at 4°C. Supernatants were removed and saved, β-hexosaminidase release was estimated in cell free supernatants and 0.1% Triton X-100 solubilized pellets, as described (Malaviya R et al., J Biol Chem., 1999, 274, 27028-38; Ozawa et. al., 1993, J. Biol. Chem., 268:1749-1756). Anaphylaxis Model:
In the murine model for antigen induced active anaphylaxis (Malaviya R et al., Targeting Janus kinase 3 in mast cells prevents immediate hypersensitivity reactions and anaphylaxis. J Biol Chem., 1999, 274, 27028-38), mice were sensitized with 2 mg BSA in 200 μl aluminum hydroxide gel (Reheis Inc., Berkeley, NJ), which induces the production of IgE response to the presented antigen. Ten days later anaphylactic shock was induced by the i.v. injection of the animals with 200 μg BSA. Mice were continuously monitored for 3 hours for signs of anaphylaxis. Mice
Male Balb/c mice (6-8 weeks old) were purchased from Charles River Laboratories (Wilmington, MA). Breeder pairs of JAK3-null mice (Nosaka et. al., 1995) were obtained from Dr. J. Ihle (St. Jude Children's Research Hospital, Memphis, TN). Animals were caged in groups of five in a pathogen free environment in accordance with the rules and regulations of U. S. Animal Welfare Act, and National Institutes of Health (NIH). Animal care and the experimental procedures were carried out in agreement with institutional guidelines. Study We compared the pharmacokinetics of the lead micellar microemulsion formulations of WHI-P 131. The WHI-P 131 plasma concentration- time curves following i.v. bolus injection of WHI-P131 formulations in mice are depicted in Figure 5. It shows that the plasma concentration time curves for the two vehicles were practically superimposable. When pharmacokinetic calculations were made, a two compartment first order pharmacokinetic model was found to give the best fit for the plasma concentration versus time curves. A summary of pharmacokinetic parameters of of the two WHI-P131 formulations, obtained using the afore-mentioned models and software programs, shows that the maximum plasma concentrations Cmax attained at the fixed WHI-P 131 dose level of 13 mg/kg were very similar. In addition, the systemic exposure levels, as measured by the AUC, were also similar.
Dynamic light scattering spectroscopy has shown that the WHI-P 131 containing microemulsions had a mean particle size of 10-25 nm, whereas micellar solutions had particle size well below lOnm. Both micellar and microemulsion formulations of WHI-P131 are biologically active and have similar pharmacokinetic profiles in vivo.
Example 15. Mast cell inhibitory "anti-allergic" activity of formulated WHI- PI 31 in vitro.
Micellar solution and microemulsion formulations of WHI-P131 were active. Figure 6 shows the mast cell inhibitory "anti-allergic" activity of these formulations in vitro. Mast cell degranulation (β-hexosaminidase release, % of total), was assessed by measuring the β-hexosaminidase levels in cell free supernatants and Triton X-100 solubilized pellets using the formula: β- hexosaminidase release, % of total = lOOx (β-hexosaminidase level in supernatant / β-hexosaminidase level in supernatant + solubilized pellet). Unformulated WHI- P131 has been previously shown to prevent mast cell degranulation and release of preformed granule-associated β-hexosaminidase in a dose-dependent fashion with near to complete inhibition at >30 μM (Malaviya R et al., Targeting Janus kinase 3 in mast cells prevents immediate hypersensitivity reactions and anaphylaxis. J Biol Chem., 1999, 274, 27028-38). As shown in Figure 6, both formulations were as effective as unformulated WHIP131 in DMSO. Virtually complete inhibition of mast cell function was achieved at a WHI-P131 concentration of 30 μM.
Example 16. In vivo anti-allergic activity formulated WHI-P131.
We tested the efficacy of WHI-P131 in a model of IgE/antigen- induced active systemic anaphylaxis. To this end, mice were first injected with BSA in an aluminum hydroxide gel to trigger a BSA-specific IgE response. Ten days later, these BSA-sensitized mice were rechallenged with this antigen to induce anaphylaxis. Only one of 20 (5%) saline treated control mice and 4 of 25 (16%>) micelle vehicle (0% WHI-P131) treated control mice did not develop fatal anaphylaxis (Table 10). The remainder of these control mice (i.e., 40 of 45) developed anaphylaxis and died within 45 min after antigen challenge. In contrast, 7 of 10 (70 %) BSA-sensitized mice that were treated with WHI-P131 (micellar formulation) prior to antigen challenge survived without any signs of anaphylaxis, (PO.05 by log-rank test).
Table 10: Protective activity of the WHI-P131 Micellar Formulation against Active Anaphylaxis in Mice.
Figure imgf000055_0001
To study the effect of WHI-P131 formulations on fatal anaphylaxis in mice, BALB/c mice were sensitized with 100 mg/kg bovine serum albumin in 200 μl of the adjuvant aluminum hydroxide gel (Reheis Inc., Berkeley, NJ), which favors the production of IgE in response to the presented antigen. Ten days later, mice were treated with two doses of WHI-P131 formulations (50 mg/kg) or vehicle intraperitoneally 10 min before and 10 min after an intravenous injection of the 10 mg/kg BSA. Mice were continuously monitored for 3 hours for signs of anaphylaxis and the mice surviving the anaphylactic reaction were sacrificed.
Figure 6 shows effects of WHI-P131 formulations on IgE receptor/Fc epsilon RI- mediated mast cell degranulation. RBL-2H3 cells were sensitized with monoclonal anti-DNP IgE, treated with WHI-P131 formulations or vehicle control compounds for lh, and then challenged with 20 ng/ml DNP-BSA for 30 min. Mast cell degranulation (β-hexosaminidase release, %> of total) was assessed by measuring the β-hexosaminidase levels in cell free supernatants and Triton X-100 solubilized pellets using the formula: β-hexosaminidase release, % of total = lOOx (β-hexosaminidase level in supernatant / β-hexosaminidase level in supernatant + solubilized pellet). Vehicle treated control RBL-2H3 cells released 37. l± 4.3 % of their hexosaminidase contents after DNP-BSA challenge. The data points represent the mean ± SEM values obtained from 3-4 independent experiments.
All publications, patents, and patent documents described herein are incorporated by reference as if fully set forth. The invention described herein may be modified to include alternative embodiments. All such obvious alternatives are within the spirit and scope of the invention, as claimed below.

Claims

WE CLAIM:
1. A pharmaceutical composition for parenteral administration comprising a poorly water soluble quinazoline compound, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable nontoxic lipid-based vehicle.
2. The pharmaceutical composition of claim 1 , wherein the compound is a dialkoxyquinazoline .
3. The pharmaceutical composition of claim 1, wherein the lipid-based vehicle comprises liposomes, microemulsions, or micellar solutions.
4. The pharmaceutical composition of claim 1 , wherein the vehicle comprises unsaturated phospholipids.
5. The pharmaceutical composition of claim 1, wherein the vehicle comprises a cosolvent.
6. The pharmaceutical composition of claim 1, wherein the dialkoxyquinazoline compound is in a corresponding pharmaceutically acceptable salt form, and the vehicle is a lipid-based cosolvent system.
7. The pharmaceutical composition of claim 1, wherein the quinazoline compound is of the formula
Figure imgf000057_0001
where:
Ra is hydrogen; halo; hydroxy; mercapto; ( -C4)hydroxy alkyl, methylenedioxy, ethylenedioxy, benzyloxy,OCF3, SCF3, SO3H, SO2F, SO2NR2R3 in which R is hydrogen or (C]-C4)alkyl and R is hydrogen, (Cι-C )alkyl, or phenyl, NR2R4 in which R2 is as defined above and R4 is phenyl, or Ra a group of the formula
Figure imgf000058_0001
in which R3 and R6 are each, independently, hydrogen, ( -C4)alkyl, or (Cι-C4)perfluoroalkyl, and R7 is hydrogen, halo, hydroxy, ( -C )alkyl, ( - C4)alkoxy, (C[-C4)hydroxyalkyl, or N(R ) in which R is as defined above; n is an integer of 1-4;
Rb is each, independently, hydrogen; halo; hydroxy; mercapto; (Q- C4)alkyl, (Cι-C4)alkoxy, (Cι-C4)thioalkyl, (Cι~C )hydroxyalkyl, nitro, cyano, methylenedioxy, ethylenedioxy, COCH3, CF3;, OCF3; SCF3; COOH; SO3H; SO2F; phenyl or phenyl substituted by a group selected from halo, hydroxy, mercapto, (Q- C4)alkyl, (Cι-C4)alkoxy, (C[-C4)thioalkyl, (C[-C4)hydroxyalkyl, amino, nitro, cyano, CF3, COOH, SO3H, SO2NR2R3 in which R2 and R3 are as defined below, and SO2F;
Ra is also benzyloxy substituted on the phenyl portion by a group defined above, NR2R3 in which R2 is H or (C,-C4)a_kyl and R3 is H, (C,-C4)alkyl, phenyl or phenyl substituted by a group as defined above;
R1 is (Cj-C4)alkyl, or a pharmaceutically acceptable salt thereof, such as an acid addition salt.
8. The pharmaceutical composition of claim 1, wherein the quinazoline compound is selected from the groups consisting of:
4-(3',5'-dibromo-4'-methylphenyl)amino-6, 7-dimethoxyquinazoline, 4-(2',4',6'-tribromophenyl)amino-6, 7-dimethoxyquinazoline,
4-(2',3',5,,6'-tetrafluoro-4'-bromophenyl)amino-6,7- dimethoxyquinazoline,
4-(4'-fluorophenyl)amino-6,7-dimethoxyquinazoline,
4-(3'-fluorophenyl)amino-6, 7-dimethoxyquinazoline, 4-(2'-fluorophenyl)amino-6, 7-dimethoxyquinazoline,
4-(4'-trifluoromethylphenyl)amino-6,7-dimethoxyquinazoline, 4-(2'-trifluoromethylphenyl)amino-6, 7-dimethoxyquinazoline. 4-(3',5'-bis-trifluoromethylphenyl)amino-6, 7-dimethoxyquinazoline. 4-(3'.5'-dibromo-4'-hydroxyphenyl)amino-6, 7-dimethoxyquinazoline. and 4-(3'-chloro-4'-hydroxyphenyl)amino-6, 7-dimethoxyquinazoline.
9. The pharmaceutical composition of claim 1 , wherein the dimethoxyquinazoline compound is 4-(4'-hydroxyphenyl) amino-6,7- dimethoxyquinazoline.
10. The pharmaceutical composition of claim 1 , wherein the dimethoxyquinazoline compound is a corresponding pharmaceutically acceptable acid addition thereof.
11. The pharmaceutical composition of claim 3, in the form of a micellar solution comprising one or more surfactants.
12. The pharmaceutical composition of claim 11, wherein the surfactant is a polyethyleneglycol (PEG) phospholipid.
13. The pharmaceutical composition of claim 11, wherein a second surfactant is a block copolymer of ethyleneoxide and proplyleneoxide.
14. The pharmaceutical composition of claim 11 , further comprises a carrier.
15. The pharmaceutical composition of claim 14, wherein the carrier is propyleneglycol.
16. The pharmaceutical composition of claim 3 in the form of a microemulsion comprising an interfacial film of surfactant molecules with a particle size of 0.1 μm or less.
17. The pharmaceutical composition of claim 16, wherein the surfactant is a copolymer ethyleneoxide and propyleneoxide, an ethoxylated castor oil, a purified soybean phospholipid, lecithin or a mixture thereof.
18. The pharmaceutical composition of claim 16, further comprising a carrier.
19. The pharmaceutical composition of claim 18, wherein the carrier is propyleneglycol, a medium chain triglyceride or monoglyceride, or a mixture thereof.
20. The pharmaceutical composition of claim 19, wherein ihe triglycerides in a triglyceride of apry lie acid.
PCT/US2000/007066 1999-03-19 2000-03-17 Quinazoline formulations and therapeutic use thereof WO2000056338A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP00914991A EP1162974A1 (en) 1999-03-19 2000-03-17 Quinazoline formulations and therapeutic use thereof
JP2000606242A JP2002539262A (en) 1999-03-19 2000-03-17 Quinazoline compound formulations and their use in therapy
AU36301/00A AU3630100A (en) 1999-03-19 2000-03-17 Quinazoline formulations and therapeutic use thereof
CA002366998A CA2366998A1 (en) 1999-03-19 2000-03-17 Quinazoline formulations and therapeutic use thereof
US09/960,464 US20020111360A1 (en) 1999-03-19 2001-09-19 Quinazoline formulations and therapeutic use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12514799P 1999-03-19 1999-03-19
US60/125,147 1999-03-19

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US09/960,464 Continuation US20020111360A1 (en) 1999-03-19 2001-09-19 Quinazoline formulations and therapeutic use thereof

Publications (1)

Publication Number Publication Date
WO2000056338A1 true WO2000056338A1 (en) 2000-09-28

Family

ID=22418397

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/007066 WO2000056338A1 (en) 1999-03-19 2000-03-17 Quinazoline formulations and therapeutic use thereof

Country Status (6)

Country Link
US (1) US20020111360A1 (en)
EP (1) EP1162974A1 (en)
JP (1) JP2002539262A (en)
AU (1) AU3630100A (en)
CA (1) CA2366998A1 (en)
WO (1) WO2000056338A1 (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7148230B2 (en) 2003-07-29 2006-12-12 Astrazeneca Ab Quinazoline derivatives
EP1890677A2 (en) * 2005-06-16 2008-02-27 Myriad Genetics, Inc. Pharmaceutical compositions and use thereof
US7910731B2 (en) 2002-03-30 2011-03-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
US7998949B2 (en) 2007-02-06 2011-08-16 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof
US8088782B2 (en) 2008-05-13 2012-01-03 Astrazeneca Ab Crystalline 4-(3-chloro-2-fluoroanilino)-7 methoxy-6-{[1-(N-methylcarbamoylmethyl)piperidin-4-yl]oxy}quinazoline difumarate form A
US8399461B2 (en) 2006-11-10 2013-03-19 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, medicaments containing said compounds, use thereof, and method for production of same
US8497369B2 (en) 2008-02-07 2013-07-30 Boehringer Ingelheim International Gmbh Spirocyclic heterocycles medicaments containing said compounds, use thereof and method for their production
US8648191B2 (en) 2008-08-08 2014-02-11 Boehringer Ingelheim International Gmbh Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
US8658654B2 (en) 2002-07-15 2014-02-25 Symphony Evolution, Inc. Receptor-type kinase modulators and methods of use
US8877776B2 (en) 2009-01-16 2014-11-04 Exelixis, Inc. (L)-malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
US10736886B2 (en) 2009-08-07 2020-08-11 Exelixis, Inc. Methods of using c-Met modulators
US11124482B2 (en) 2003-09-26 2021-09-21 Exelixis, Inc. C-met modulators and methods of use

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6126917A (en) * 1999-06-01 2000-10-03 Hadasit Medical Research Services And Development Ltd. Epidermal growth factor receptor binding compounds for positron emission tomography
GB9922171D0 (en) * 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
CA2691914C (en) * 2007-07-11 2012-06-26 Pfizer Inc. Pharmaceutical compositions and methods of treating dry eye disorders
BE1030538B1 (en) 2022-05-18 2023-12-19 Bogaert Gina Van Liposomal preparation containing encapsulated hormones, method of production and use

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0082385A1 (en) * 1981-12-18 1983-06-29 Troponwerke GmbH &amp; Co. KG 1-(3-Nitrophenyl)pyrido(2,3-d)pyrimidine-2,4(1H,3H) diones and 1-(3-nitrophenyl)quinazoline-2-4(1H,3H)diones as cutaneous medicaments
US5411963A (en) * 1988-01-29 1995-05-02 Dowelanco Quinazoline derivatives
US5449678A (en) * 1994-01-11 1995-09-12 Agricultural Research Organization, Ministry Of Agriculture Anti-fibrotic quinazolinone-containing compositions and methods for the use thereof
WO1996006616A1 (en) * 1994-08-31 1996-03-07 Davidson, Clifford, M. Quinazolinone pharmaceuticals and use thereof
US5792771A (en) * 1992-11-13 1998-08-11 Sugen, Inc. Quinazoline compounds and compositions thereof for the treatment of disease
WO1998038984A2 (en) * 1997-03-05 1998-09-11 Sugen, Inc. Formulations for hydrophobic pharmaceutical agents
WO1998051284A1 (en) * 1997-05-13 1998-11-19 Imarx Pharmaceutical Corp. Novel acoustically active drug delivery systems

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0082385A1 (en) * 1981-12-18 1983-06-29 Troponwerke GmbH &amp; Co. KG 1-(3-Nitrophenyl)pyrido(2,3-d)pyrimidine-2,4(1H,3H) diones and 1-(3-nitrophenyl)quinazoline-2-4(1H,3H)diones as cutaneous medicaments
US5411963A (en) * 1988-01-29 1995-05-02 Dowelanco Quinazoline derivatives
US5792771A (en) * 1992-11-13 1998-08-11 Sugen, Inc. Quinazoline compounds and compositions thereof for the treatment of disease
US5449678A (en) * 1994-01-11 1995-09-12 Agricultural Research Organization, Ministry Of Agriculture Anti-fibrotic quinazolinone-containing compositions and methods for the use thereof
WO1996006616A1 (en) * 1994-08-31 1996-03-07 Davidson, Clifford, M. Quinazolinone pharmaceuticals and use thereof
WO1998038984A2 (en) * 1997-03-05 1998-09-11 Sugen, Inc. Formulations for hydrophobic pharmaceutical agents
WO1998051284A1 (en) * 1997-05-13 1998-11-19 Imarx Pharmaceutical Corp. Novel acoustically active drug delivery systems

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"VIDAL 1997", XP002143626 *
BRASSINNE C; ATASSI G; FRUHLING J; PENASSE W: "Anti-tumor activity of a water-insoluble compound entrapped in liposomes on L1210 Leukemia in mice", JOURNAL OF THE NATIONAL CANCER INSTITUTE, vol. 70, 1983, pages 1081 - 1086, XP002142785 *
SCWINN J; SPRINZ H; LEISTNER S: "The effects of a thio-containing quinazolinedione derivative (MECH) on the lipid oxidation in bilayer liposomes", JOURNAL OF RADIOANALYTICAL AND NUCLEAR CHEMISTRY, vol. 232, no. 1-2, 1998, pages 35 - 37, XP000929184 *
YIV SH; METZ M, LI M, LIU X-P: "Microemulsion, liposome and mixed micellar formulations for a poorly water soluble quinazoline derivative", ABSTRACTS OF PAPERS AMERICAN CHEMICAL SOCIETY, vol. 217, 21 March 1999 (1999-03-21), pages 148, XP000929164 *

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7910731B2 (en) 2002-03-30 2011-03-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
US8343982B2 (en) 2002-03-30 2013-01-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclic heterocyclic compounds pharmaceutical compositions containing these compounds, their use and process for preparing the same
US8658654B2 (en) 2002-07-15 2014-02-25 Symphony Evolution, Inc. Receptor-type kinase modulators and methods of use
US9359332B2 (en) 2002-07-15 2016-06-07 Symphony Evolution, Inc. Processes for the preparation of substituted quinazolines
US10266518B2 (en) 2002-07-15 2019-04-23 Symphony Evolution, Inc. Solid dosage formulations of substituted quinazoline receptor-type kinase modulators and methods of use thereof
US9796704B2 (en) 2002-07-15 2017-10-24 Symphony Evolution, Inc. Substituted quinazolines as receptor-type kinase inhibitors
US7148230B2 (en) 2003-07-29 2006-12-12 Astrazeneca Ab Quinazoline derivatives
US11124482B2 (en) 2003-09-26 2021-09-21 Exelixis, Inc. C-met modulators and methods of use
EP1890677A2 (en) * 2005-06-16 2008-02-27 Myriad Genetics, Inc. Pharmaceutical compositions and use thereof
EP1890677A4 (en) * 2005-06-16 2013-01-30 Myriad Genetics Inc Pharmaceutical compositions and use thereof
US8399461B2 (en) 2006-11-10 2013-03-19 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, medicaments containing said compounds, use thereof, and method for production of same
US7998949B2 (en) 2007-02-06 2011-08-16 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof
US8497369B2 (en) 2008-02-07 2013-07-30 Boehringer Ingelheim International Gmbh Spirocyclic heterocycles medicaments containing said compounds, use thereof and method for their production
US8772298B2 (en) 2008-02-07 2014-07-08 Boehringer Ingelheim International Gmbh Spirocyclic heterocycles medicaments containing said compounds, use thereof and method for their production
US8088782B2 (en) 2008-05-13 2012-01-03 Astrazeneca Ab Crystalline 4-(3-chloro-2-fluoroanilino)-7 methoxy-6-{[1-(N-methylcarbamoylmethyl)piperidin-4-yl]oxy}quinazoline difumarate form A
US8648191B2 (en) 2008-08-08 2014-02-11 Boehringer Ingelheim International Gmbh Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
US8877776B2 (en) 2009-01-16 2014-11-04 Exelixis, Inc. (L)-malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
US9809549B2 (en) 2009-01-16 2017-11-07 Exelixis, Inc. Malate salt of N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N′(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer
US11091439B2 (en) 2009-01-16 2021-08-17 Exelixis, Inc. Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer
US11091440B2 (en) 2009-01-16 2021-08-17 Exelixis, Inc. Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)- N′-(4-fluorophenyl)cyclopropane-1,1 -dicarboxamide, and crystalline forms thereof for the treatment of cancer
US11098015B2 (en) 2009-01-16 2021-08-24 Exelixis, Inc. Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
US10736886B2 (en) 2009-08-07 2020-08-11 Exelixis, Inc. Methods of using c-Met modulators
US11433064B2 (en) 2009-08-07 2022-09-06 Exelixis, Inc. Methods of using c-Met modulators

Also Published As

Publication number Publication date
JP2002539262A (en) 2002-11-19
US20020111360A1 (en) 2002-08-15
CA2366998A1 (en) 2000-09-28
AU3630100A (en) 2000-10-09
EP1162974A1 (en) 2001-12-19

Similar Documents

Publication Publication Date Title
WO2000056338A1 (en) Quinazoline formulations and therapeutic use thereof
US6258820B1 (en) Synthesis and anti-tumor activity of 6,7-dialkoxy-4-phenylamino-quinazolines
AU690958B2 (en) Treatment of platelet derived growth factor related disorders such as cancers using inhibitors of platelet derived growth factor receptor
EP1682552B1 (en) Tocopherol-modified therapeutic drug compounds
US20080045559A1 (en) Tocopherol-modified therapeutic drug compounds
US20060276491A9 (en) Therapeutic compounds
US20060003976A1 (en) Cholesterol/bile acid/bile acid derivative-modified therapeutic drug compounds
US8258145B2 (en) Method of treating brain cancer
US10376591B2 (en) Formulations and carrier systems including farnesylthiosalicylic moieties
CN101287369A (en) Method of treating brain cancer
EP2697206B1 (en) Heterocyclic compounds and uses thereof in the treatment of sexual disorders
AU2007327048B2 (en) Amino quinazolines derivatives with blood platelet reducing properties
US8304420B2 (en) Substituted quinazolines for reducing platelet count
MXPA06004429A (en) Tocopherol-modified therapeutic drug compounds

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 36301/00

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2366998

Country of ref document: CA

Ref country code: CA

Ref document number: 2366998

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 606242

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 09960464

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2000914991

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000914991

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000914991

Country of ref document: EP